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This study evaluates the supports that Enterprise Ireland is currently providing to start-
up companies in the Irish Life Science sector by exploring how seven different Irish 
start-ups within the sector have utilised  the support system. 
This study found that the current Life Science support network within Ireland was found 
to be effective at funnelling potential start-ups into the Enterprise Ireland support 
system and it was also found companies with reasonable business plans are receiving 
the required level of funding and support to scope out their business plans. In all seven 
companies studied, Enterprise Ireland funding and support was sufficient for the 
business to navigate the difficult first year following formation / spin-out.  
At approximately the one year mark the way in which each company interacted with 
Enterprise Ireland diverged significantly. The companies who were successful in 
securing revenue from external investors grew quickly and generated a significant level 
of employment, whereas the companies that could not secure this funding stalled in 
their development. In two cases there was difference of opinion between Enterprise 
Ireland and the founders of the companies with respect to the future development of 
the business, this had a negative impact on how the companies engaged with the 
support processes. 
Overall it was concluded that the current support system provided by Enterprise Ireland 
is performing well when it comes to the identification of viable candidate companies 
and is offering the supports needed in the critical early stages of business 
development.  
Two key areas where the current offerings require improvement were identified; firstly, 
more assistance is needed for companies who are having difficulty securing external 
sources of funding as this was a significant road block to business development. 
Secondly, the depth of Enterprise Ireland business mentors within the Life Science 
sector requires development as a number of companies could not gain access to the 








Within Ireland the Life Science industry, in particular the pharmaceutical and 
biotechnology sectors, accounts for approximately 31% of nominal GDP (€50bn) and 
this sector has largely outperformed other areas during the recent economic downturn 
(Mac Coille & Gorman 2012). Ireland possesses a highly skilled workforce and a 
competitive tax system which has given the country the ability to attract multinational 
organisations; currently eight of the world’s top ten pharmaceutical companies have a 
manufacturing presence in the country (PharmaChemicalIreland 2014).  
However the much publicised “Patent Cliff” hit the industry hard in 2013 as many of the 
“block buster” drugs produced in Ireland came off patent (for example, Singulair and 
Lipitor) and this directly contributed to Pharma exports decreasing in August 2013 by 
€1,420m (17%) in comparison with August 2012 (Ryan 2013). Current estimates show 
that a drug will lose approximately 80% of its value within the first year after patent loss 
due to generic substitution, therefore companies who lose patent protection on a drug 
must then significantly cut their costs in order to remain competitive within the open 
market (Mac Coille & Gorman 2012). Also the number of generic manufacturers has 
grown strongly over the last decade, while traditional Big Pharma has been in decline – 
figure 1 shows how the industry has changed since the early 1990’s (Hunt et al. 2011).   
 




Another significant trend within the industry is the merging of large international 
pharmaceutical corporations which is then inevitably followed by significant 
“consolidation programs” aimed at reducing costs by cutting the headcount and 
outsourcing production to lower cost regions of the globe. Some examples of this  
practice include, Merck Sharpe and Dohme (MSD) acquiring Schering Plough for $41.1 
billion in 2009 - this lead to a headcount reduction of 24,000 across the combined 
company within a four year period and the closure of a number of production facilities, 
including two in Ireland (Thomas 2013) (Rockoff 2009). Another pharmaceutical giant 
Pfizer purchased Wyeth Pharmaceuticals in 2009 for $68 billion; at the end of 2008 
Pfizer had 81,800 employees and Wyeth had 47,426, which was a combined total of 
129,226. By the end of 2013 a total of 51,000 job cuts were made across the combined 
company which reduced the overall headcount to the same level as Pfizer alone in 
2008 (Staton 2014). These two mergers resulted in the loss of over 75,000 jobs within 
the industry in just five years.  
Ireland has not been immune to these trends within the macro industry. Some reports 
suggest that the patent cliff has directly resulted in a 20% drop in the total pharma 
workforce within Ireland (O’Riordan 2012). The table below highlights just some of Big 
Pharma manufacturing facilities that have announced closures or large redundancy 
programs in the last three years, many of which are the result of mergers and 
acquisitions that led to an excess of capacity.  
 
Site Name Estimated Number of Jobs Lost 
MSD Swords 570 (BusinessEtc 2013) 
Pfizer Newbridge 150 (Burke 2013) 
MSD Rathdrum 280 (Kennedy 2013) 
Pfizer Cork 177 (O’Riordan 2012) 
Beckman Coulter Galway 140 (Siggins 2014) 
Bristol-Myers Squibb Dublin 160 (RTE 2014) 
Arkopharma Waterford 18 (McSorley 2015) 
Total Job Losses 1495 







1.2 Research Purpose and Significance of Research: 
 
Ireland’s ability to influence global industry trends within the Life Science sector is 
relatively limited and one can expect that fluctuations in the macro industry will 
continue for some time to come; this in turn will lead to volatility within the Irish Life 
Science sector. A potential solution to this external volatility is to grow the number of 
smaller indigenous Life Science companies within Ireland which can then complement 
the current multinational presence and dilute Ireland’s overall exposure the global 
industry trends.  
Some groups within Ireland, such as PharmaChemical Ireland, have recognised this 
opportunity and responded by launching a strategy that aims to divert more investment 
into development activities which are research intensive and potentially high reward 
(Moran 2013). This approach is based on an acceptance that the industry is changing 
and the traditional large scale manufacture of bulk pharmaceutical products is likely to 
diminish in Ireland. The group argue that the impact of this negative trend could be 
mitigated by growing on the left side of figure 2 (i.e. increase the focus on R&D and the 
commercialisation of products developed in Ireland). The PharmaChemical Ireland 
Director accurately described the current situation when he stated “If the industry in 
Ireland is to survive and prosper, it needs to remain strategically relevant – this means 
investment in the development of new technologies” (Moran 2013). 
 
 
Figure 2: Drug Development Timeline (Moran 2013). 
  
One obvious way to grow the number of small R&D focused Life Science companies in 




companies and nurture them from the laboratory bench into the formation of a viable 
business. Growing the number of Life Science start-ups within Ireland will have a 
significant multiplier effect within the wider economy as Life Science companies have 
the ability to create employment across a broad range of skill sets, including academic 
Professors, PhD graduates, third level graduates and manufacturing staff. A study 
carried out by the Pharmaceutical Research and Manufacturers of America (PhRMA) 
which assessed “The Economic Impact of the U.S Bio-pharmaceutical Industry” found 
that the average compensation of a worker in this area was more than twice the 
average U.S private sector compensation and the industry is a significant generator of 
tax intake for the overall economy due to high wages and high value product 
manufactured (PhRMA 2013). Therefore growing the number of jobs in this space will 
have a larger impact on the national economy in comparison with growing jobs in other 
sectors of the economy.  
However, starting a Life Science company is extremely challenging as Life Science 
companies, by their very nature, are high risk ventures that can require a significant 
amount of funding just to get to the “proof of concept” stage of development. Typically a 
further ten years of development is required before the company has a product which it 
can actually sell to end users. A report published by the Tufts Centre for the Study of 
Drug Development (CSDD) suggested that the cost of developing a new drug now 
exceeds $2.5 billion and that this is only set to increase over time (Mullin 2014).  
 
 





The CSDD also found that only 21.5% of drugs that start phase 1 clinical trials actually 
make it to the market, but just to get a product to phase 1 clinical trials requires millions 
to be invested (Medical Marketing 2003). Therefore it is clear that creating an 
environment that will support start-up companies within the Life Science sector is not a 
simple undertaking.  
 
1.3 Research Objective and Structure:  
This study focuses on Irish start-ups within the Life Science industry and aims to 
evaluate the current supports available from the perspective of companies who have 
actually used the support mechanisms and from the perspective of the government 
body (Enterprise Ireland) that is responsible for delivering the supports to the sector. 
An exploratory sample of seven companies was selected to represent the full range of 
disciplines within Irish Life Science sector. Each company was profiled, a founding 
member interviewed and their experiences with the support systems was assessed. 
The overarching goal was to provide a meaningful evaluation of the indigenous Irish 
Life Science sector and to identify potential measures which could be taken to improve 
the overall number and the success rate of start-ups. 
 
1.4 Research Question:  
The primary research question which has been addressed by this dissertation is as 
follows; 
“How are Irish Life Science start-up companies using the supports offered by 
Enterprise Ireland and are these supports meeting the needs of each company?” 
Prior to collecting the primary data needed to answer this question, a literature review 
was completed in order to identify the major academic theories and models in the field 
of Life Science start-up support. These academic theories and frameworks were then 
used to construct the primary research methodology, evaluate the primary data 







Chapter 2: Literature Review 
 
2.1  Introduction: 
A wide range of academic studies have been completed within the field of Life Science 
start-up support mechanisms. This volume of research has resulted in a large number 
of varying opinions on how best to nurture young highly technical companies and equip 
them for a successful future. This literature review identifies the major themes which 
have been researched within the field and examines the potential uses of this research 
within the Irish Life Science sector.  
 
2.2 Cluster Model: 
Cooke (2002) examined the innovation support systems that have been established in 
Germany, Cambridge US, Massachusetts and Cambridge UK. His research assessed 
the capabilities and limitations of public and federal attempts at developing innovation 
systems which focused on building regional structures based on core technological 
capabilities which were already in place in the form of Universities (Cooke 2002). In his 
paper “Biotechnology Clusters as Regional, Sectorial Innovation Systems” it is argued 
that the biotechnology sector, like many other segments of the Life Science sector, is 
knowledge driven, therefore firms will have a tendency to “cluster” around knowledge 
sources. This work can be related directly to the current situation in Ireland, which has 
a number of world class academic research institutes located within a relatively small 
geographic area, therefore the creation of a cluster support system or governance 
structure to capitalize on this fundamental asset (the asset being a strong core of 
technical knowledge based in a small geographic area) could be of significant benefit 
when it comes to assisting new start-up companies. A system which allows for the free 
exchange of knowledge while consolidating the resources needed to start a business 
may suit Ireland, as opposed to providing isolated supports at various universities. 
Issues relating to Intellectual Property (IP) protection can create significant road blocks 
when it comes to the creation of a system where knowledge is freely shared and IP 
risks could result from a lack of engagement from candidate companies and research 
groups.   
Leibovitz (2004) also completed a case study on the use of the “cluster concept” to 
develop the biotechnology sector within the Scottish cities of Glasgow and Edinburgh; 




culture and resources (Leibovitz 2004). This research found that the key factors in 
growing the sector are the size and diversity of the labour market available, the 
presence of research institutions, and the public provision of infrastructure and 
supports. The three elements identified through this paper seem obvious at first, 
however the creation of an environment that contains all three variables is challenging. 
One could argue that Ireland possesses a diverse labour market within the Life Science 
sector and the required research institutions, but the provision of public infrastructure 
and supports may be an area that could be enhanced. An assessment of the 
infrastructure provided to start-up Life Science companies within Ireland forms part of 
the primary research for this dissertation as it is a key element in development of the 
sector.  
A significant proportion of the “cluster model” research which has been completed 
within the Life Science sector has been based on the analysis carried out by Porter 
(2000). His research forwarded the theory that the establishment of clusters of similar 
companies within a relatively small geographic area can lead to economic competitive 
advantages and an environment that will nurture innovation, efficient productivity and 
strong employment growth (Porter 2000). Although the cluster model approach may 
support innovation and create an environment in which start up Life Science 
companies can flourish, it could be viewed as idealistic and in practice it may prove too 
difficult to create a cluster that contains all the required amenities. Due to the very 
nature of the Life Science industry there will always be some level of dependence on 
external relationships, such as suppliers, customer based and regulatory agencies.  
Shiri M. Breznitz (2013) examined the sustainability of the Life Science cluster in Israel 
by asking the question “Can an industry centred on one part of the production cycle 
become sustainable?”(Breznitz 2013). Based on survey findings and in-depth 
interviews the author contends that Israel has been successful in gathering the 
necessary academic expertise and funding from government sources to create a Life 
Science cluster. The goal of creating such a cluster was to generate a concentration of 
firms within close geographic proximity which should in theory allow the smaller 
companies to enjoy the benefits of large-scale industrial production and technical 
innovations. These innovations would simply be beyond the scope of the individual 
small firms. However, the author also found that the sector in Israel is stuck in the R&D 
space and is suffering from a lack of knowledge of later stage Life Science production, 
limited funding and a fragmented social network – these issues have limited the 
clusters ability to develop further and contribute to the local economy. The author 




Israel has negatively impacted on the ability of the local workforce. As a result, the 
current Life Science cluster within the country will remain unsustainable until this issue 
is resolved.  
This research is an example of how the cluster approach (while seeming viable on 
paper) can only be successful if all of the necessary elements are present i.e. Israel 
has the academic institutions and there is a political desire to create a viable Life 
Science industry, but has a lack of experience in bringing products to market. By 
comparing the current Israeli situation to the Irish Life Science industry one can see 
that Ireland has a distinct advantage due to the presence of a large number of mature 
multinational pharmaceutical and biotechnological companies; as stated previously, 
eight of the world’s top ten pharmaceutical companies currently have a manufacturing 
presence in Ireland (PharmaChemicalIreland 2014). Many of these companies have 
had a presence in Ireland for over 50 years (such as MSD Rathdrum which was 
founded in to 1960’s) and this has resulted the creation of a highly experienced 
indigenous workforce which is proficient in all elements of the manufacturing process 
i.e. from R&D through to bulk manufacture and sales. This pool of talent could be used 
to help the start-up companies within Ireland grow and develop into successful viable 
businesses.   
Although the creation of Life Science “clusters” is not within the scope of this research 
project, a number of the themes identified as part of the academic research into cluster 
formation (such as the elements needed to create an environment where Life Science 
start-ups can grow and the issues faced by other countries when they attempted to 
implement the cluster model) were used when assessing the role Enterprise Ireland 
within the Irish support system. These issues were also used to reinforce the 
recommendations made by this dissertation.  
 
2.3 Comparison Studies: 
A number of comparison studies have been completed on the success of the Life 
Science industries in various regions. One example would be a  report which detailed a 
direct comparison of the Irish and Portuguese innovation systems with respect to 
biotechnology (Calvert & Senker 2004). The report highlighted that although both 
counties have a relatively low budget when it comes to investment in R&D, the Irish 
biotechnology sector largely outperformed its Portuguese counterpart over the period 
assessed. Ireland, unlike Portugal, developed specific policies directed at 




that was capable of supporting research & development thus creating a mechanism of 
potentially commercialising the knowledge originating from Universities. Also the 
establishment of BioResearch Ireland (BRI) programme, under the governance of 
Enterprise Ireland, further facilitated the commercialisation of R&D. This body was 
tasked with developing the infrastructure to support the national biotech industry 
(Calvert & Senker 2004). The BRI eventually lead to the creation of another support 
structure known as Science Foundation Ireland (SFI), which was developed under the 
Irish National Development Plan (NDP); the stated remit of the SFI was “build and 
strengthen scientific and engineering research and its infrastructure in the areas of 
greatest strategic value to Ireland's long-term competitiveness and development”(SFI 
Ireland 2013).  
SFI has employees based within five Universities and the total investment budget 
allocated to the SFI was in the region of €1.4 billion (UniversityWatchdog 2009). The 
creation of such supports and an investment in R&D of €12.4 million per million capita, 
compared to €7.3 million per million capita in Portugal, allowed for the growth of the 
biotechnology sector within Ireland. This growth can be quantified by comparing the 
number of  biotechnological patent applications between 1995/96 to 1999/00 (Calvert & 
Senker 2004). Figure 4 clearly shows how Ireland outperformed Portugal over the 
period in question.  
 
Figure 4: Number of Biotechnology Patent Applications, Ireland vs. Portugal (Calvert & 
Senker 2004) 
 
It could be argued that the relative success of Ireland in the last number of decades, in 




provided to the sector in Ireland was almost twice that of Portugal and the impact of the 
current support structures have been somewhat overstated. With the current economic 
climate exacting funding pressures on all governments, the ability to generate the 
levels of funding required to bring a Life Science products to market cannot be 
provided by the government alone and additional private funding plays a critical role. 
However, securing private investment in new Life Science products is extremely 
difficult due to the fears that the product may never make it to market; statistics on the 
failure rates of new therapeutic products estimate that only one in 5,000 candidate 
pharmaceutical products ever make it to market and even the drugs that make it 
through the research & development stage into clinical trials only have a 20% chance 
of making it to market (Urbig et al. 2013).  
Comparison studies are valuable tools when one is seeking to assess the performance 
different countries support mechanisms relative to each other. During the collection of 
primary data for this dissertation, the use of comparison studies and benchmarking as 
a means of measuring Enterprise Irelands performance relative other small open 
economies was assessed in order to evaluate how Enterprise Ireland support 
mechanisms are developed and if the learnings from other geographic areas are 
reviewed when creating policies. Also the issue of securing private investment on the 
open market was reviewed with all seven companies’ studied in this dissertation and 
was a key point of discussion with Enterprise Ireland.  
 
2.4  Effect of Public Policies: 
In general, the majority of the research in the area of supporting Life Science start-ups 
focuses on the effectiveness of public policies. Enzing et al. 2004 approached this area 
from a different perspective by asking the question “do dedicated public policies 
matter?”  (Enzing et al. 2004). The authors compared the commercial performance of 
the biotechnology sectors across fourteen different EU Member States and assessed 
the impact dedicated public policy had on the growth of the national industry. The 
public policy instruments implemented in the fourteen countries between 1994 and 
2001 were compared using four indicators; 
1. Number of Patent Applications in Biotechnology 
2. Number of Biotech Companies 
3. Amount of Venture Capital Invested in Biotechnology 




In terms of performance in these four areas, the three Nordic countries (Denmark, 
Sweden and Finland) all performed the strongest. Interestingly none of these countries 
have dedicated policies. This data set was used to classify each country as “Above 
Average, Around Average and Below Average”. The authors conclude that dedicated 
government instruments are not required to deliver a high performing biotechnology 
sector and that generic policy which is not specifically targeted at one individual sector 
is just as effective. They attempt to explain why the Nordic counties are outperforming 
the other fourteen countries by putting forward the following key points; 
1. The Small Country Effect – Smaller counties have an advantage due to their 
geographic proximity to open economies and they also have strong internal 
networks due to the relatively low geographical distance between key 
stakeholders (similar to the “cluster” model discussed in section 2.2). This 
proposal is supported by peer research. 
2. Quality of the “Generic” Instruments – The authors propose that the level of 
support offered from the generic instruments in the Nordic countries in many 
cases outperformed the “dedicated supports” used in other countries. However 
there is an acknowledgment that there isn’t sufficient public data available to 
draw any definitive conclusions.    
3. Systematic Approach to Innovation – Adopting a systematic approach to 
supporting innovation by offering support to all areas of the innovation pathway 
is far more important than having dedicated policies targeted at specific areas 
and neglecting others (Reiss et al. 2004). The Nordic countries have adopted a 
systematic approach to great effect.  
One clear counter argument to these finding is that only three countries with no specific 
policy (Denmark, Sweden and Finland) scored “Above Average” and the only countries 
to score “Below Average” also had no dedicated public policy at the time of the study. 
No countries with dedicated policies scored “Below Average”. One could conclude that 
Denmark, Sweden and Finland are outliers or that their generic public policies are well 
developed and this is why they are outperforming other countries as opposed to 
coming to the conclusion that “Dedicated public policies do not matter.” Due to the 
importance of public policy in supporting start-ups, an assessment of the EI policies 
and how they are formed was included as part of the primary research in this 
dissertation.  
This research completed by Enzing et al also highlights the importance of using 




mechanism. Although this dissertation does not specifically evaluate the “need” for Irish 
support policies, the importance of using the appropriate indicators was considered 
when assessing how EI measures its success on an annual basis. Also, indicators 
such as job creation and EI supports utilised were used in the findings section of this 
report when comparing the “success” of each of the seven start-ups.  
 
2.5  Commercialisation of Academic Research: 
The “commercialisation of academic research” is another common theme observed 
when one reviews methods of growing the number of successful indigenous companies 
in the Life Science sector. Uctu and Jafa (2013) considered the emerging 
biotechnology industry in South Africa and assessed the “first structured attempts to 
equip scientists to build a bridge between the science of biotechnology and the 
commercialisation of knowledge in the field” (Uctu & Jafta 2013). The authors 
introduced the term “bio-entrepreneurship”, which they describe as wealth creation that 
comes from Life Science discoveries in the laboratory that are applied in a commercial 
market. They discuss the differences between traditional entrepreneurs and bio-
entrepreneurship (see figure 5) and put forward “three pillars” (Managerial Skills, 
Sufficient Capital, Access to new technology leading to products) that underpin the 
success of a start-up biotech company (Hine & Kapeleris 2006)(Uctu & Jafta 2013).  
 
Figure 5: Traditional entrepreneur’s vs.  Bio-entrepreneurs(Uctu & Jafta 2013) 
 
The authors found that the initial policies implemented in South Africa were largely 
effective based on feedback from participants and made a number of interesting 
recommendations, such as; the incorporation of bio-entrepreneurship teaching into 




entrepreneurs and the creation of a dedicated agency to “champion bio-
entrepreneurship”. Although the Life Science industry in Ireland can be considered 
more developed, the issues identified in this study of South Africa are still relevant and 
applicable to an Irish setting as it can be difficult to find an individual who possesses 
the business and management acumen to complement their scientific capabilities. The 
creation of effective leadership teams, as opposed to relying on one individual to 
deliver on all fronts, can be a potent method of forming a successfully start-up 
business. This topic was assessed as part of the primary research section of this 
dissertation; the ability of Irish Life Science start-ups to implement effective 
management structures and EI’s role in that process was reviewed. The “three pillars” 
discussed by the authors were also identified in the more successful companies 
studied as part of this dissertation, this further supports that the work compared by 
Uctu & Jafta is applicable to the Irish sector.  
Penin & Wolff (2010) completed a body of work analysing what is needed to for a 
successful start-up in the biotechnology sector by analysing four different start-ups in 
the Upper Rhine Biovalley (Peinin & Wolff 2010). The four companies were selected on 
the basis that they were young (all started between 1999 and 2001), were hosted by an 
incubator in Strasbourg and all operated in the human health area. Each company was 
profiled using qualitative interviews with the founders, queries in multiple data bases 
and questionnaires. The overall plight of each company is detailed in the figure 6.  
 
Figure 6: Overview of each company studies (Penin and Wolff, 2010) 
 
Firm A was described as the “Success story…..without the happy ending”. It 
originated from an academic spin-off and secured €30 million from two rounds 




to 160 by 2006. Unfortunately the firm went bankrupt in 2005 as it failed to raise 
sufficient funding to sustain its high growth. “Quick growth without turnover” was 
identified as the key to the company’s failure.  
Firm B grew to 40 employees by 2005 and secured over €55 million in private 
funding. The company showed significant promise but closed in 2006 due to 
poor performance in clinical trials which resulted in loss of investor confidence.   
Firm C never really got off the ground. It is a very good example of how a lack 
of finance in the early stages can effectively kill off any chance of creating a 
thriving biotech company.  
Firm D was the only company studied which managed to generate a turnover 
and survive. It grew to 20 employees, turned over €750,000 in 2003 and 
€797,000 in 2004. In comparison to the other three companies, this firm had the 
most focused business plan and had a cash flow strategy that sustained the 
company as it grew. This example highlights the importance of implementing a 
strong business model to complement scientific research and also emphasises 
the importance of effective leadership within a start-up venture.  
The “lessons learned” from each of the companies experiences highlighted three key 
areas where start-up biotech company’s need to perform;  
1. Human Capital – the entrepreneur needs the have aspirations linked to their 
culture and the ability to grasp opportunities. Entrepreneurs with previous 
managerial experience or start-ups that had a dual team of scientific 
manager and executive manager stood the best chance of success.  
2. Social Capital – recognition that biotech companies do not grow in isolation 
and having a strong network is critical. Building and leveraging this network 
will have a profoundly positive impact on the business.  
3. Physical Capital – the ability to patent and protect your technology is a 
central aspect of the businesses success. The authors argue that in the 
biotech sector, firms rely on patents much more than in other sectors. 
The stories of the four companies described by Penin and Wolff bore a striking 
resemblance to the seven Irish companies studied during this dissertation and the 
“lessons learned” that were identified by the authors were used when evaluating the 
success or failure of the Irish companies. Common links between the plights of each 
company were examined as potential areas for improvement.  A similar approach to 




presenting the findings of this study. Collecting data using this method allowed to the 
comparison of a number of very different companies and it also allowed for the 
identification of common issues faced by all companies.   
 
2.6  Incubators:  
As previously stated, Life Science companies can be notoriously difficult to grow due to 
their need for seed capital, R&D support, overcoming regulatory hurdles and the 
identification of appropriate business partners. An “incubator” support structure (such 
as the one used in Strasbourg discussed in section 2.5) can address the key early 
needs of the start-up company and can be an effective method of building a strong 
foundation for the business. Smilor and Gill (1986) stated that the most effective 
“incubator seeks to effectively link talent, technology, capital and know-how in order to 
leverage entrepreneurial talent and to accelerate the development of new companies” 
(Smilor & Gill 1986). Incubators can also offer intangible benefits to young companies 
such as credibility, networking opportunities, access to suppliers, access to potential 
customers and access to potential employees – all of which makes it easier for the 
entrepreneur to secure additional investment and grow the business (Smilor 
1997)(Totterman & Sten 2005).  
One example of a successful Life Science incubator is the award winning University of 
Florida (UF) Sid Martin Biotechnology Incubator (Breedlove 2014). This incubator was 
opened in 1995 and accommodates academic spinouts developing therapeutic, 
diagnostic, drug delivery, ag-bio and bio-energy products. To date, forty seven 
companies have used the facility and these companies have raised in excess of $1 
billion in funding from investors. The facility has also had a number of extremely 
successful graduates in the recent past, such as;  
Nanotherapeutics: Won a $358 million contract with the U.S Department of 
Defence and has begun the construction of a 165,000 sq. ft drug development 
and manufacturing facility which will create 150 jobs at an expected average 
salary of $90,000. 
Pasteuria Bioscience: A gene therapy company was acquired by Syngenta for 
€113 million. 
Applied Genetic Technologies: Launched a $50 million IPO.  




These four success stores occurred over a two year period and the facility was 
selected from 1,900 members in 60 countries for the 2013 Randall M. Whaley 
Incubator of the award, for overall excellence. The Director of the UF incubator 
highlighted five key areas as the “Ingredients of Success”; 
1. Highly Specialized Physical Infrastructure:  
As Life Science start-ups require significant capital investment in laboratory 
space to perform their work, they can seldom afford to purchase their own in 
order to start the business. The incubator adopted a “Lean Start-up” approach 
by sharing office space and almost $1 million of core scientific equipment. This 
method allowed the UF incubator to maximise the return on capital investment 
by ensuring all facilities are used efficiently.  
 
2. Vigorous Research Ecosystem: 
A robust pipeline of Life Science research is fundamental to the success of any 
incubator program and the UF incubator director states that the “build it and 
they will come” approach simply does not work. Therefore a successful 
incubator needs to actively seek new opportunities and partner with institutions 
that have strong technology licencing operations that understand how to 
commercialize research. Well-funded Universities often provide the ideal 
knowledge and talent pipeline required to establish the climate necessary to 
create a successful incubator space.  
 
3. Collaborative Culture and Responsive Management: 
The managers of the incubator must strive to create an environment that is 
lively, welcoming and prioritises the interactions between peers, mentors and 
the service providers. Adopting this approach creates a collaborative culture 
within the incubator and creates a “mini cluster” of businesses who can feed off 
each other to the benefit of the overall program.  
 
4. Effective Talent Screening:  
The selectivity in accepting clients is a critical element to success. The UF 
incubator uses a Biotechnology Advisory Committee (BAC), which is a team of 
venture capitalists, bio-entrepreneurs, regulatory specialists and other experts 
to review company applications and make recommendations on admissions. 
Companies entering the incubator are given one-year renewal terms and are 




the incubator to make space for other more promising ventures. This rigorous 
screening approach ensures that the resources are used to support the best 
possible portfolio of companies at any point in time. It avoids the situation where 
poor performing companies are allowed to languish for years and drain 
resources, which is an issue commonly faced by other incubator programs. 
Also, UF incubator tries to keep at least one lab available at all times, this 
allows the program to accommodate a promising company at short notice and 
minimises the risk of turning down a promising opportunity. To date the 
incubator has not turned down a company that was a “good fit” and is averaging 
a 90 percent occupancy rate. 
  
5. Comprehensive Goal Measurement: 
Picking the right metrics to measure the performance of the incubator is critical 
and the Director states that measures such as sales per incubator are often 
poor indicators. The UF tracks metrics such as  companies admitted, number 
graduated, survival rates (to date only 12 of the 47 companies admitted have 
failed), total funding, regulatory progress, patents, corporate partnerships, 
acquisitions, IPO’s and number of products to market. Local jobs created is also 
another key measure of success; between 2004 – 2010 graduate companies 
created 1,467 local jobs and generate $100 million per year to the local 
economy.  
 
Another interesting step taken by this incubator was the elimination of professor-led 
companies. This decision followed a review of the program structure which found that 
professor-led companies were a “fundamental flaw” in the incubator strategy and that 
the recruitment of experienced bio-management coupled with aggressive courting of 
venture capitalists yielded more successes. The incubator is adamant that helping 
start-ups with the early recruitment of experienced bio-business management adds 
credibility to the venture and gives confidence to potential investors – similar to the 
“bio-entrepreneur” effect discussed in section 2.5. This strategy has developed to a 
point where the University of Florida will not licence its technology to a company unless 
it is led by an “investible CEO”; it is believed that this practice has been part of the 
formula for improved success. This system is significantly different to the current Irish 
approach as the majority of Irish Life Science start-ups are led (at least in part) by the 




interviewed during the course of this dissertation. These findings also seem to indicate 
that the installation of an effective leadership or “investible CEO” could be a vital key to 
success. Enterprise Ireland’s role in identifying experienced business partners for Irish 
Life Science start-up was explored as part of this study. 
Salvador and Rolfo (2011) completed a study on the effectiveness of incubators and 
science parks for the creation of spin off companies using Italy as the subject of the 
case study (Salvador & Rolfo 2001). The authors describe the development of the 
public policy initiatives aimed at supporting research spin-off over the last number of 
decades. They found that in the 1970s and 1980s the primary focus was centred on the 
creation of science and technology parks, described as “a property-based initiative that 
has formal and working links with a University or other higher education institution or 
research centre”.  
But more recently the attention of public policy makers has focused on the role of the 
University in the development of localised spinouts. This can be seen globally through 
the creation of internal structures within Universities focused on technology transfer 
(such as liaison offices and incubators) and the increase in the number of new firms 
created from academic research. Italy followed this trend of public policy development 
by supporting science parks throughout the 1980s (by the end of the 1990s there was a 
science park in almost every region in Italy) and then through the implementation of 
regulations regarding the creation of technology transfer offices (TTO’s) and Liaison 
Offices (ILOs) in the 2000’s (Nosella & Grimaldi 2009). This evolution in policy is very 
similar to the path taken by Ireland. The authors began their research into the 
effectiveness of these policies by identifying spin-offs in all of Italy’s 20 regions and 
then mapping the number of science parks and incubators in each of these regions. 
They identified over 400 research spin-offs and found that there were no significant 
differences between the “on-park” and “off-park” firms i.e. the on-park firms were not 
outperforming the off-park firms, however they did conclude that “positive judgement of 
the hospitality and the key importance of geographic proximity to the host structures to 
the university as well as the international attitude of the on-park spin-offs are important 
proofs of the soundness of the current Italian policies”.  
The authors then constructed a statistical regression model which confirmed the 
hypothesis that research spin-off firms are growing in number within Italy, “particularly 
in areas where there is a higher number of science parks and incubators”. They found 
that most of the public policy energy is focused on increasing the number of spin-offs 




empirical research identified that the majority spin-offs in Italy are classified as “micro-
firms” as opposed to SME’s according to the European Union classification. 
The findings from this study are particularly relevant to the current situation in Ireland 
and it suggests that although incubators do have a positive effect on the number of 
spin-offs created, they should be very selective when choosing companies to support 
i.e. do not just focus on creating another spin-off, focus on creating a company that 
may have the potential to develop and grow into an SME’ or multinational business. 
Salvador and Rolfo (2011) made reference to a body of work completed by Bearse 
(1998) which asked the question “do Harvard students (the incubates) succeed 
because of what Harvard (the incubator) did for them or because of the selection 
criteria undertaken by Harvard that selected only successful students, regardless of 
what Harvard did to them” - this quote sums up the attitude successful incubators 
should take when selecting potential candidate companies.  This is also a highly 
relevant finding when it comes to assessing the goals of Enterprise Ireland (EI), who 
have set targets to grow the number of start-ups significantly and use the number of 
High Potential Start-Ups (HPSU) created as one of their measures of success – this 
point is discussed further in a section dedicated to an assessment of EI. Ireland may 
potentially be falling into the same trap as the Italian model by simply focusing on 
growing the number of start-ups as opposed to focusing on increasing the success rate 
of start-ups. This is an area which was scrutinised when interviewing a representative 
from EI during the course of this dissertation.  
Although the majority of research carried out on incubators focuses on the positive 
effect they have on business development, there are a number of potential issues 
when it comes to starting a business in an incubator. McAdam and Marlow (2007), 
completed a study of a business incubator unit in the Republic of Ireland located on a 
Science and Technology Park linked to a university (McAdam & Marlow 2007). The aim 
of this particular incubator studied was to support new Irish start-ups that had 
significant growth potential. Following an in depth analysis of 12 firms who used the 
incubator, the authors found that although the incubator offered a number of benefits to 
the firm in the early years (such are the benefits discussed above), tensions began to 
emerge as firms grew within the incubator space and concerns over privacy, protection 
of intellectual property and competiveness strategies became genuine issues for the 
firms. Also as new firms joined the incubator space they may not be welcomed by 
mature companies who viewed them as potential threats.  The study identified that 
most firms remain within the incubator for three years before they move to an 




time frame. It is recommended that the relocation of firms should be encouraged as it 
ensures that the mature company is not constrained in its development and that newer 
firms can gain access to the supports. The authors also recommended that the role of 
management within the incubator should be examined to ensure it is not inadvertently 
creating barriers to greater entrepreneurial independence.    
While the use of incubators is outside the scope of this dissertation (primarily because 
the Enterprise Ireland support system does directly oversee Irish incubators such as 
NovaUCD), a number of themes which are discussed in the research of Life Science 
incubators were used when assessing the current Irish support system. The 
“ingredients of success” discussed in this section were also used to frame the issues 
various companies were facing and were used when forming recommendations.  
  
2.7  Enterprise Ireland Support Structures for Life Science Start-ups:  
As previously stated, Enterprise Ireland (EI) is the primary support structure for Irish 
Life Science start-ups and the vast majority of start-ups will have some interaction with 
this government funded body during their development. The mission statement of EI is 
“To accelerate the development of world-class Irish companies to achieve strong 
positions in global markets, resulting in increased national and regional 
prosperity”(Enterprise Ireland 2015). The body employs 800 people within 10 specific 
Irish offices and across 32 international offices spanning all continents and sits under 
the Department of Enterprise, Trade and Innovation. EI works in tandem with other 
government supports bodies such as Science Foundation Ireland (SFI), Forfas and IDA 
Ireland to support and grow the Life Science space within Ireland, as depicted in the 






Figure 7: Enterprise Ireland relationship with other government bodies (O’Neill 2011) 
 
The EI support mechanism aims to provide the necessary supports across the full 
lifecycle of a start-up business, from idea generation to technology development, 
licencing the technology and ultimately to the formation of a spin out company. The 
support structure which primarily focuses on the commercialisation of viable academic 
research in the Life Science sector is the National Technology Transfer System, which 
seeks to transfer the research outputs into industry. The term Technology Transfer 
refers “the process of moving the commercial outputs of a research project out of a 
higher education institute and into a company”.  Technology Transfer Offices (TTO) 
have been set up in all of the major academic institutions and these offices act as the 
initial point of contact between the potential entrepreneur and the EI supports (O’Neill 
2011). This model is very similar to the Italian model presented by Salvador and Rolfo 
(2011) which was discussed in section 2.6.  
The Technology Transfer System was launched under the “National Strategy for 
Science, Technology and Innovation” and since its introduction in 2007 there has been 
a marked increase in the “Commercialisation Performance” of Irish start-ups in the Life 
Science sector. Figure 8 shows the impact of the program on the level of start-up 
activity within the Irish sector since its introduction (this data was presented in 2011 by 









Once a start-up becomes a “client company” of EI and engages with the support 
structures, the system is designed to offer holistic service which covers all areas of 
business development and attempts to get the start-up thinking globally from a very 
early stage in their development, as depicted in figure 9.  
 
 
Figure 9: Supports offered to client companies (O’Neill 2011) 
 
Although the supports on offer by EI are clearly defined, seem comprehensive and are 
being utilised by an increasing number of start-up companies, there is a relatively 
limited amount of data available on how start-ups are actually using the EI supports 
and if they are realising any benefits. This dissertation aims to bridge that knowledge 
gap by identifying how target companies are interacting with the support system, and 




2.8  Literature Review Conclusions and Conceptual Framework:  
As previously stated, the primary research question addressed by this dissertation is 
“How are Irish Life Science start-up companies using the supports offered by 
Enterprise Ireland and are these supports meeting the needs of each company?” This 
literature review has identified that there is wide range of opinions and approaches 
available when attempting put a system in place that will nurture and support start-up 
companies in the Life Science sector. The peer reviewed research themes and best 
practices identified during this literature review, coupled with the assessment of the 
current Enterprise Ireland offerings was used frame an assessment of the Irish support 
system and to form recommendations on how the current Irish system could be 
improved.  
The research methodologies used by some of the authors discussed in this literature 
review (particularly authors such as Peinn & Wolff) were also used when constructing 
the research methodology & methods for this dissertation (discussed further in Chapter 
3), as these methods have been sown to yield the primary data required to draw 





Chapter 3: Research Methodology and Methods 
 
3.1 Introduction and Research Paradigm: 
As identified by the studies discussed in Chapter 2, there is a broad variety of methods 
and strategies which can be utilised when researching support structures for the Life 
Science industry. These strategies can range from large quantitative experimental 
surveys completed over a long periods of time designed to track the overall 
performance of an entire sector, to detailed case studies of specific companies 
designed to assess the plight of a single business.    
In order to answer the primary research question posed by this dissertation, the 
research paradigm (which can be described as a belief system that will guide the way 
in which we do things) of the author was evaluated prior to developing the research 
design (ERM 2014). This research  takes a Post Positivism view of the Irish Life 
Science sector as it aims to take into account the context of the situation when making 
judgements and the primary data was collected with the understanding that previously 
held theories or human knowledge are often based on conjecture and opinion 
(Robinson 2002). This dissertation aimed to challenge “opinions” about the Irish Life 
Science Sector and remove bias by using sound research methods that were free from 
feelings.  The collection of primary data from subject matter experts representing all 
areas of the Irish Life Science landscape was identified as a means of removing bias 
and could also be used to form a rounded view on the current status of the industry. 
This method also allowed for the identification of the challenges that Life Science 
companies are facing and the issues that need to be addressed in order to create an 
environment where indigenous companies can grow. One potential issue with adopting 
this research philosophy was the ability to gain access to the relevant individuals who 
could provide the insight necessary to generate meaningful findings on the industry. 
The identification of targets for interview was a fundamental to the quality of the 
research findings. 
  
3.2 Research Philosophy and Approach: 
In order to generate the high quality primary data needed for this dissertation a number 
of research strategies were assessed. It was concluded that a qualitative interview 
based research strategy was the best method for the collection of primary data as this 
method provided the flexibility needed to understand the very different development 
pathways used by each of the companies studied. It also allowed for the data to be 




companies. A quantitative survey / questionnaire approach was also assessed but it 
was concluded that this method would not have provided the flexibility needed, as 
generic surveys could not capture the large variation between the companies targeted 
by this study.  
Once the research philosophy was identified, a set of criteria was developed to aid the 
selection of interview candidates.  The following criterion was applied when selecting 
candidate companies and individuals for interview; 
 
1. The company must be of Irish origin. 
2. The company must operate within the Life Science sector.  
3. The company must be based on a novel concept, technology or service i.e. no 
“copycat” companies who were attempting to mimic an existing business were 
within scope.  
4. The company must have engaged with Enterprise Ireland at some point in their 
development.  
5. The company must have set out with the goal of bringing a product or service to 
market which had the potential to create employment within Ireland. 
6. The interviewee must be a founding member of the company or the current 
CEO.  
7. The companies interviewed must represent the full spectrum of the Life Science 
sector and all candidates must not operate within the same space e.g. not all 
Biotech based.  
 
3.3 Research Strategy: 
A total of seven companies were selected based on the criteria listed in section 3.2; 
reference Table 2 for the name of each company and the representative interviewed. 
These seven companies offered a comprehensive analysis of the full indigenous Irish 
Life Science sector as they covered virtually all disciplines – including, 
pharmaceuticals, biotechnology, medical diagnostic, waste water treatment, 
biodegradable production and contract service provision. The purpose of selecting 
companies from each of these areas was to get an exploratory sample of the full breath 
of the sector and to eliminate the issue of bias toward one sub group. The interview 
candidates identified were also high quality as they were founding members of each 
organisation; this was a critical element in the collection of meaningful primary data.  
After a review of the Enterprise Ireland senior management team, Mr. Brian O’Neill was 




manager for High Potential Start-ups in the Industrial and Life Science Industry and 
was ideally placed to provide the EI perspective on supporting the Irish Life Science 
sector.  
 
Interviewee: Company:  Position:  Life Science 
Field:  
Prof. Kevin O'Connor Bioplastech Ltd Founder and CEO Biodegradables 
Prof. Eoin Casey OxyMem Ltd Co-Founder Water Treatment 
Prof. William Gallagher Oncomark Ltd Co-Founder and Chief 
Scientific Officer 
Diagnostics  
Dr. Mark Barrett APC Ltd Co-Founder Pharmaceutical 
and Biotech 




Prof. Kingston Mills Opsona 
Therapeutics Ltd 
Co-Founder Biotech 
Prof. John Gilmer  Solvotrin 
Therapeutics Ltd 
Co-Founder, Chief 
Technical Officer and 
Director of Research 
Pharmaceutical 
Mr. Brian O'Neill Enterprise 
Ireland 
Manager of High 
Potential Start-Ups in 
the Industrial and Life 
Science Industry 
Enterprise Ireland 
Table 2: Interviews carried out as part of primary research 
 
3.4 Research Design and Collection of Primary Data: 
Each company was then profiled and a founding member / current CEO was asked a 
series of standard questions which set out to address the following topics (reference 
Appendix for an example interview transcript);  
 During the initial stages of development did the Start-up approach EI or did EI 
make the first contact? 
 What supports were offered and how were they used?  
 Were additional supports (outside the ones offered by EI) used by the 
company?  




 What were the most significant issues the company faced during its formation 
and did EI provide the necessary assistance?  
 Could the company have started without EI support?  
 Are EI still involved today?  
 Were there any specific strengths or weaknesses with the overall process? 
 Based on the companies experience, what changes would they like to see 
made to the EI offerings?   
The findings from the interviews with the start-up companies were used to guide the 
line of questions put to the EI representative in order to gain the EI view on the major 
themes identified (reference Appendix for transcript of this interview).   
 
3.5 Approach to Data Analysis: 
The company profiles and interviews findings were collated and a number of common 
issues were identified. A similar analysis method to the one used by Penin & Wolff 
(2010) was utilised and a table was constructed which compared the development of 
each company. The findings were reviewed against the themes identified during the 
literature review section prior to the formation of recommendations. This method of 
data analysis ensured that the resulting recommendations were supported by facts and 
peer reviewed research, as opposed to just giving the authors “opinion” on the Irish Life 





Chapter 4: Research Findings 
 
4.1  Introduction:  
The following is an overview of each company assessed during the course of this 
research and the findings from the interviews carried out with the founding members / 
current CEO’s. The findings from the interview with the Enterprise Ireland Manager for 
HPSC are also documented in this section  
 
4.2 OxyMem Limited:  
 
Figure 10: Oxymem Official Company Logo 
Oxymem Limited originated from the University College Dublin (UCD) School of 
Chemical and Bioprocess Engineering and spun out from the college in 2013 following 
ten years of product development (Oxymem 2015). The company has developed a 
novel, patented biofilm control system which is used in the treatment of waste water. 
The Oxymem “Membrane Aerated Biofilm Reactor” (MABR) is considered a 
breakthrough technology in waste water treatment and the product can be retrofitted to 
existing waste water system or can be installed in new treatment plants (Oxymem 
2015). Since it spun out in 2013 Oxymem has received a number of  prestigious 
awards including the 2015 Enterprise Ireland Knowledge Transfer Ireland Impact 
Award for Best Spin-out and it was named the 2014 Start-up of the year at the Bank of 
Ireland Start-up awards (Oxymem 2015).   
Oxymem is a client company of Enterprise Ireland and raised €250,000 in seed funding 
from EI which it used to open its manufacturing facility in Athlone and employ six direct 
staff (McAleer 2014). The company successfully secured a further €2 million in a 
funding round in 2014 and grew its employment to twelve people (UCD 2014). 
Currently the company employs 30 people (figure quoted by Prof. Eoin Casey) and the 
stated goal is to grow turnover to €50 million within the next five years.  
Professor Eoin Casey, who was a founding member of the company and current 
company Chairman, was interviewed about the origin of the company and how it 
interacted with Enterprise Ireland. When asked what supports the company leveraged 




but they (EI) would have put us in touch with commercial partners through a business 
partner program which is something they don’t always do but they did with us. Basically 
they bring together the start-ups and entrepreneurs who are interested in setting up a 
business based on University research”. Through this process, Oxymem then found a 
business partner. Prof. Casey stated, “We decided to go down the route of forming a 
business based on this partnership and formed an alliance between us, UCD and this 
entrepreneur who was looking for a new opportunity”.  “Over at least a year prior to 
spinout, we had engagements in the form of weekly meetings between us, UCD and 
the investor. That was us working through the business plan, financial calculations, and 
technical specifications. The outcome was a business plan”. During this period no 
additional funding from outside sources was required as the business partner provided 
the necessary funds (on top of the initial EI investment) to develop the business prior to 
spin-out. Also, as the business partner had significant previous experience in the 
business world and brought a “been there – done that” level of knowledge to the 
company. The company did not need to seek additional assistance in the form of a 
business mentor from a support function. When asked, would it have been possible to 
find this business partner without the assistance of EI and if the EI are still involved in 
the company today, Prof. Casey stated “It wouldn’t have been possible without EI”; EI 
no longer take an active role in the company and “they don’t have a director appointed, 
but they would have set some certain milestones as part of their conditions for 
investment that we are required to meet as part of that agreement”.  
EI gave key support to Oxymem in the early stages of the business development and 
Prof. Casey stated “they (EI) are not in the business of going into major rounds of 
investment; that is not what they do. The next rounds of investment will be larger 
international players who specialise in the kind of business we are in”. In terms of the 
vision and strategy for the company, Prof. Casey stated “Oxymem was always based 
on high volume sales to international markets from the very beginning and never had 
any intention to focus on the Irish market and then expand. The vision was always 
thinking very big, so the early stages were to prove the product at an industrial scale, 
develop partnerships and to come up with a manufacturing process that was scalable 
to meet a major global demand for the product.” This vision matched the EI criteria for 
a HPSU as the company was focused on internationalisation and quickly employed in 
excess of 10 people within Ireland. When asked about the company’s overall 
experience with EI, Prof. Casey stated “EI have been great, very professional and very 
supportive. You couldn’t ask for better support”; “because of what we were offering 




in Ireland EI were very, very supportive. Their level of interest and support is probably 
proportional to the vision of the company in terms of what it wants to do”.  
In summary, Oxymem Limited can be considered an Irish innovation success story, it 
was founded on novel scientific innovation which was developed within an Irish 
academic institution and has created a product offering that is considered as best in 
class within its industry. One of the keys to Oxymem’s success was the identification of 
an experienced business partner at an early stage of the company development – this 
partnership was facilitated by EI. This added management and business acumen 
complemented the innovative scientific technology. Also, focusing on a single product 
and developing a strong business plan (under the guidance of an experienced 
business partner) prior to spinning out from UCD allowed the company to grow quickly 
and made it easier for them to present the value proposition of Oxymem to potential 
investors. This in turn allowed the company to secure the necessary funding from 
external investors to grow the business. The Oxymem story emphasises the 
importance of the right management team when it comes to the success of a start-up 
venture. The EI supports offered to Oxymem met all of the companies needs and 
helped the organisation to mature to a point where it is now self-sufficient. 
Oxymem is a real world example of “bio-entrepreneurship” (which was described 
earlier in section 2.5 as  “wealth creation that comes from Life Science discoveries in 
the laboratory that are applied in a commercial market”) happening in Ireland with the 
support of EI (Uctu & Jafta 2013). Oxymem have implemented the “three pillars” which 
were described by Uctu & Jafta 2013 as “Managerial Skills, Sufficient Capital and 
Access to new technology leading to products” and as a result the company continues 














4.3 Bioplastech Limited: 
 
Figure 11: Bioplastech Official Company Logo 
Bioplastech Limited is a company focused on green technologies which offer 
alternatives to petrochemical polymers and their derivatives (Bioplastech 2015). The 
company originated in University College Dublin and spun-out in 2009. Bioplastech 
produces a range of biodegradable polymers made by bacteria which were developed 
in the research laboratories of UCD. The primary polymer produced is 
Polyhydroxyalkanoate (PHA) which belongs to a group of polymers with diverse 
physical properties and can be used to manufacture a range of products including 
biodegradable plastics, elastics, rubbers and glues.  The company uses waste 
materials from other industries, such as agricultural and petrochemical waste, to feed 
the bacteria who then produce the biodegradable PHA’s – therefore the technology 
developed by Bioplastech addresses the full life cycle of waste materials (Bioplastech 
2015). 
The company has had some involvement from Enterprise Ireland and received proof of 
concept funding to further develop a method of converting PHA into biodegradable 
plastics and to investigate the scalability of the process. The company also won the 
2008 NovaUCD start-up of the year award and secured additional VC funding from two 
angel investors (CSCB 2008). It used these funds to employ a team of scientists, rent 
laboratory space in UCD and begin working on their product range. Bioplastech 
currently employs four people and is still based on the UCD campus; it is yet to bring a 
product to market.  
Professor Kevin O’ Connor, co-founder and current CEO of Bioplastech, was 
interviewed about the process of starting the company and his interactions with the 
Irish support structures. Following a number of years of research within the UCD 
microbiology department, Prof.O’Connor approached the NovaUCD incubator with his 
invention disclosures and began the process of filing a patent. Representatives from 
NovaUCD then suggested that he should spin out a company based on the technology 
he developed and Bioplastech entered the NovaUCD campus company development 
program, coming third. When asked about his experience in dealing with NovaUCD; 
Prof. O’Connor stated “It was very good, but frustrating in many ways because you are 
operating in a space where you have no real clue. People you are working with do not 




telling you to do certain things and you are saying to yourself “that will never work” and 
then you are telling them certain things and they are saying “that will never work.” I 
found it a very intensive process although it was beneficial to the business as we 
learned a lot from it” - “It is a very different mind-set going from the academic world into 
a business mind-set.”  
When asked about Bioplastech’s involvement with EI Prof.O’Connor stated “We were 
reluctant to engage fully with EI. We have engaged a lot in some ways, they were very 
good in pushing us to understand the market, what are the real commercial 
opportunities, where are your weaknesses – that has been very good. However we 
have been reluctant to be a client company of EI because we knew from day one that 
the goals didn’t match and that our timeline was slower than theirs and that if we got 
involved with them then we would be on a road to failure. I think EI recognised that as 
well. EI wanted to push us to do certain things, but we knew there was a downturn in 
the economy and that there was no money out there and we were going to have to do 
things in other ways. Having said that, I still report into EI to keep them updated as I 
think it is important to keep that relationship. But we are not a full client company of EI 
– I would say that we are in-between”.  
The company “pivoted” a number of times during its development and has changed its 
business model from a biodegradable production company, to a technology 
development company which seeks to develop products using the biodegradable 
polymers it produces. Prof. O’Connor noted that the company may have spun out too 
early, “however by spinning out early we learned a lot and actually probably moved in 
the right direction because we were immediately faced with the commercial questions 
from other people” such as EI representatives. The financial investment received from 
the angel investors has been consumed by product development and the company has 
branched out into contract work in order to generate a cash flow for the business.  
When queried about Bioplastech’s overall view of the EI supports, Prof. O’Connor 
stated “EI were really good because they really helped by challenging what is your 
business plan? Who are you targeting? What is your offering? When are you going to 
target them? What do your financials look like?  All of these different questions were all 
very good”. “One thing I think that is lacking is highly qualified knowledgeable advisors. 
EI have a series of advisors who are consultants but to me they do not know about the 
tech space. So I would definitely say that that is a gap that these guys are suddenly 
thrown into biotech and don’t have the expertise”. “I’m not sure if it can be addressed 




that EI put me in contact with and it was just a waste of time”. “Another weakness is 
cash – cash is a major weakness for everybody. The VC community in Ireland is small 
and does not have a lot of cash. Therefore they are looking for everything – big returns, 
short turnarounds etc. The reality is that companies in our space in other countries 
such as the USA and China are having millions spent on them”. When asked if there is 
a possibility of locating the right advisors for companies such as Bioplastech Limited 
within Ireland Prof. O’Connor stated “the Kerry Group have some activity in developing 
biotech and I have another technology which I might spin out into a new company 
which the likes of Kerry and others would be useful as they will have an understanding 
of that technology. It is a balance between telling them about your technology and 
telling too much and it is gone.” 
When asked about the future plans for the business Prof O’Connor stated, “We want to 
go to pilot scale and to start to validate the scaling to product which will allow us to 
develop further products. In seven years’ time we will hope to be in a partnership with 
someone who will actually be producing the polymer for the market. To get to that next 
level we need a third party to come in and work with us - we have one company that 
already have a pilot plant so we are hoping to use them and put our technology into 
their pilot. This way there is no capital expenditure only some slight modifications. This 
would possibly cost €100k as opposed to multiple millions to start from scratch”. 
Bioplastech can be classified as a company founded on a promising technology but is 
yet to realise its full commercial potential. Enterprise Ireland have made attempts at 
guiding the company by injecting some initial seed funding and providing mentors, 
however a lack of technical understanding within EI about Bioplastech’s potential 
product offerings coupled with the availability of sufficient funding to grow the company 
to the next level seems to be stunting the company’s progress. Another issue identified 
was the fundamental misalignment between EI and the Bioplastech CEO on the vision 
for the future of the company and its potential to grow rapidly – this is in contrast to 
Oxymem who shared the EI vision of rapid internationalisation. The Bioplastech 
development story highlights the potential pit falls of spinning out too early. When the 
company spun out in 2009 it did not have a clear vision of the final product, target 
markets or a definitive business plan – this then created a lag period following spin-out 
where the company put a lot of energy into addressing these areas. The advice and 
guidance of a suitably qualified and experienced mentor may have addressed these 
issues at a far early stage and allowed the company to grow, however EI did not seem 
to have such a mentor within its support system therefore the company had to work 




It could be said that Enterprise Ireland was not sufficiently equipped with the internal 
expertise or the finances to address some of the key issues which were facing 





4.4 APC limited: 
 
Figure 12: APC Official Company Logo 
APC limited is a chemical engineering solutions company which services 
pharmaceutical, biopharmaceutical and contract manufacturing operations (CMO) to 
ensure the delivery of robust and scale-independent production processes. The 
company spun-out in 2011 from the School of Chemical and Bioprocess Engineering in 
UCD and is still located on campus. APC currently works at a global scale with 
companies in R&D, commercialization, manufacturing and technology development. Its 
staff of 60 consists of chemical engineers, process chemists and analytical chemists 
with PhD, Post Doc and industrial pharma experience (APC 2015). The company’s 
mission statement is “From lab bench to manufacturing, we bring innovation to process 
design and development” and its aim is to deliver unique solutions to its clients which 
reduce the risk, cost and time to market for new and existing pharmaceutical products. 
Since its formation, APC has added many of the world’s top 10 multinational 
pharmaceutical companies to its client list (NovaUCD 2011). The company won the 
NovaUCD 2011 Start-up of the year Award and was the overall winner of the 2011 
NovaUCD Campus Company Development Program, which is a program supported by 
Enterprise Ireland (NovaUCD 2011).    
The current CEO and co-founder, Dr Mark Barrett, was interviewed about the spin-out 
of the company and how it interacted with the Irish supports. Dr. Barrett stated, “APC 
was started by myself and my co-founder Professor Brian Glennon out of the school of 
chemical and bioprocessing in UCD. We essentially were doing a lot of applied 
chemical engineering with a lot of the multinationals within Ireland. As a result, there 
was a large research consortium called the solid state pharmaceutical cluster which 
brought together all of the leading academics and pharmaceutical companies within 
Ireland. I was doing a lot of research within that consortium and it allowed us to engage 
with the pharmaceutical community which we had previously not been able to engage 
with. Under that umbrella we began to develop a lot of activity and realized that some 
of the technology we were developing and the research capabilities were incredibly 




created the early momentum required to establish the company. This happened in late 
2011 and APC was formed. We hired our first two employees and by year end 2015 we 
will be up to approximately 60 employees, which are about 50% PhD qualified chemical 
engineers and about 50% PhD qualified scientists so it’s a very large research and 
R&D focused team. One of the attributes that is very interesting is that we are the 
largest employer of PhD qualified chemical engineers in Ireland so there is a lot of 
really skilled scientists and engineers and we have developed a company and eco 
system that is catering towards high end R&D. Sometimes you just don’t get that within 
the manufacturing community in Ireland and it is an alternative for people who are 
seeking a technical driven career progression.” 
In terms of supports used, he stated “The one thing that you are aware of when you 
start a company is everything costs money, so there are just overheads associated 
with everything – from lab rental to advertising jobs, hiring people, pension 
contributions, equipment depreciation. One of the first things we looked at was ways to 
kick off our revenue cycle. We identified two ways, one was we kick started our 
engagements with two companies who put a lot of faith in myself and Brian, there was 
no real organizational structure or equipment base but they gave us a chance and 
those two companies would still be our biggest partners. In parallel to that we started to 
engage with Enterprise Ireland and they have been fantastic in terms of supporting us. 
It probably took about a year to get the tangible support but it has been tremendous. 
Even now we are working with them (EI) on another grant. They initially supported us 
with a large R&D grant, I think we were one of the first start-ups under the HPSU to 
obtain a large R&D grant, which is a grant more often provided to medium and large 
enterprises. That really helped initiate our research strategy in both small and large 
molecules.”  
When describing the company’s initial dealings with EI, Dr. Barrett stated “it took a bit 
of time working with EI for them to obtain clarity on our vision, what our purpose was 
and how we were going to achieve our business plan. We were essentially claiming 
that we were going to do big things quite quickly and I think that there is a lot of history 
of companies telling that to EI and not delivering. We on the other hand were in an 
environment where we were delivering so they were extremely supportive of us. We 
are still working with them on grants, training and employment expansion.”  “They had 
a number of representatives within their Life Science division that were very supportive. 
They see a very broad application within the Life Science sector and the origins of APC 
was almost a niche within a niche so it took a bit of time to talk through things and I 




delivering where as we are very confident of our ability to deliver. Once they saw that 
they prioritized their time with us and in turn prioritized the assignment of the R&D 
grant”. In addition to finance, APC were also supplied with an EI mentor; “we were 
assigned a HPSU representative and he was great. He visited us a lot and was really 
keen on understanding how we were progressing. We have now developed beyond the 
HPSU space and we are classed as a medium sized established company so we have 
different representatives. It’s going really well and I was delighted with the process 
because it was during the recession in Ireland and they were more than 
accommodating. They were never trying to personalize the revenue or the income of 
the company. They were always looking at the best interests of the tax payer and I 
think that went really well – I have nothing but respect for how they helped us.” 
From his dealings with EI it was very apparent to Dr. Barrett that “a real key element to 
EI is jobs and jobs creation. We graduated from the HPSU and met our new 
representative, at the time we committed to having 34 jobs by now but we have 50 so 
they are really focused on the jobs. Also the fact that the jobs we have created are PhD 
and research focused has meant that EI have tried to come up with support in any way 
possible. They would come up with milestones and advise you on what to put in based 
on your revenue cycle and job cycle to date which is a very informative process and 
very helpful.” 
Unlike many other companies who start-up within the Life Science industry, APC had a 
service that was immediately available to customers, therefore the challenges faced 
when setting up the business were very different to traditional Life Science startups. Dr. 
Barrett stated “not having any operational systems to run the company from business 
development, pipelines, internal systems, revenue systems, financial planning and 
modeling systems to HR systems, consumable purchasing, and space utilization 
systems. The company now is really being driven by all of this information which has 
allowed us to develop these systems and it feels very much like an operations 
business. You take for granted all of these systems that allow you to do your job, at the 
start we didn’t have anything like that, therefore we were trying to grow the company by 
a few hundred percent every year whilst trying to establish those systems – so I would 
say that was the biggest challenge. However, we were extremely fortunate that we 
were not relying on venture capital to grow, therefore we were allowed to focus on 





One area where APC has encountered difficulties is in the cross over between EI and 
the IDA. Dr Barrett stated “we work with all of the Pharma companies within Ireland – 
who are all FDI investments managed by the IDA very closely, obviously we are an 
Irish company so we work with EI very closely.” – “it is quite difficult to engage across 
the IDA because we are not a multinational so the responsibility lies with EI, but we are 
helping the IDA based companies.”, “EI look after the Irish companies and the IDA look 
after the foreign companies, and that is brutally how they play it. I just think that an 
environment that is more conducive to enabling APC or companies like us to really 
drive research initiatives into these foreign multinationals, because the work that we 
are doing is so transformational in its impact, if it could be facilitated it would be a 
fantastic outcome for all.” A more collaborative approach to business supports where 
information is shared freely is in alignment with the “cluster model” discussed earlier (in 
Section 2.2) and would help in the development of companies such as APC Limited.  
APC has successfully found a niche within the Irish Life Science industry and is quickly 
becoming a significant employer within the sector. The main benefit to EI when 
supporting companies such as APC, who are offering a service to the industry as 
opposed to a specific medicinal product, is that they do not need regulatory approval to 
sell their service, they are labor intensive, they require highly educated personnel and 
can scale very quickly. EI identified the potential within APC at a very early stage and 
offered every support possible to the company – this support allowed the company to 
grow without the need for VC funding which in turn allowed the founders to keep 
control of the organization. This was crucial because the company founders retained 
full control of the business and were allowed to grow into other areas, therefore the 
business developed rapidly and new opportunities emerged. The EI supports provided 
to APC limited addressed the companies needed in its first year which gave the 
company time to secure service contracts from a number of key customers and this 









4.5 Opsona Therapeutics Limited: 
 
Figure 13: Opsona Official Company Logo 
Opsona Therapeutics Limited was spun-out from Trinity College Dublin in 2004. It has 
developed a series of new candidate pharmaceutical products and strategies which 
treat and prevent autoimmune, inflammatory diseases as well as cancers and other 
infectious diseases (Opsona 2015). The companies mission statement is “We discover 
and develop therapeutics to restore balance to the immune system and to improve the 
quality of life of patients - this is achieved by the development of new compounds 
through the dedication and commitment of all our people.” (Opsona 2015) 
Since its formation, Opsona has had a very impressve track record when it comes to 
raising funds for prooduct development. Initially it was funded by Enterprise Ireland and 
its co-founders, the company then completed a financing round in 2004 where it raised 
€6.25 million from a number of external sources (Enterprise Ireland 2004). This round 
of investment was facilitated by Enterprise Ireland who introduced Opsona to the main 
third party investor (Genentech) through the BioLink USA-Ireland program, a 
networking body facilitated by Enterprise Ireland (Enterprise Ireland 2004). The 
company went on to secure an agreement with the multinational pharmaceutical 
company Wyeth to collaborate on the development of a new treatments for chronic 
inflammatory diseases in 2006, for which it received a number of “milestone payments” 
(Opsona 2015). In 2009 a further €18 million in funding was raised from a round which 
enabled it to expand both at an operational and clinical level. In that same year, the 
company opened a new facility in Switzerland to complement the Dublin operations 
and is further developing its portfolio of candidate compounds. Also in 2009 the 
company raised a further €3.3 million from the Roche Venture Fund and Enterprise 
Ireland, which brought the total money raised in 2009 to €21.3 million and put the 
company on a strong financial footing. In 2011, the company was awarded €5.9 million 
from the European Commission “to lead a European framework 7 (FP7) consortium of 
research and clinical groups (termed MABSOT) in the advancement of clinical trials for 
its lead drug candidate OPN-305 in solid organ transplantation” (Opsona 2015). In 
2013, the company raised another €36 million from existing investors and new 




A co-founder of the company, Professor Kingston Mills was interviewed about 
Opsona’s journey. When asked how the company began, Prof. Mills stated “It started in 
2004 when I, Luke O’Neill and Dermot Kelleher had intellectual property which we filed 
with the University and were really not doing much with it. Then Mark Heffernan came 
along, he went around the Irish University system looking at various IP portfolios and 
came to meet us individually first and then collectively, having previously reviewed our 
IP. He then said there was a case to set up a start-up company around our IP. We 
agreed and within a matter of weeks the company was setup. That was the beginning 
of it.” Mark Heffernan became the CEO of the company and had significant previous 
experience due to his involvement in two Biotech start-ups in Australia. The newly 
formed company then approached EI for funding in the first year, when asked about 
their interactions with EI Prof. Mills stated “we needed to pay a salary to Mark who 
became the full time CEO. Therefore we needed funding to cover his salary. We also 
needed money for completing pitches and traveling, so we approached EI for some 
seed funding and they were very helpful in that initial year. Then we went out to raise 
an A round and we got funding from a local venture fund, Seroba, from Genentech in 
California, and from Inventages who are a Nestle VC fund in Switzerland.” The three 
investment funds “were just a fraction of the funds we pitched to as there were not 
many options in Ireland – there never has been and there still isn’t local VC’s that the 
Biotech sector will get funding from so you have to go outside the country. Certainly for 
bigger rounds which involve more money you won’t get it in Ireland – there just isn’t the 
funding or the appetite for risk in Ireland that there is in Europe for the United States.”  
Prof. Mills stated that EI “were very much involved in the first couple of years in terms 
of helping us and we actually managed to secure funding from a number of EI 
mechanisms when starting the business. EI are very good at the inception of the 
company; I’ve had this experience with two companies, but they are not so good at 
following on so they tend to help the company in the very early stage. Once they have 
invested an amount of money they are very reluctant to follow through. I suppose you 
might say that that is their job, just get things going. But there is a valley where some 
companies get stuck. Opsona was lucky enough to be able to go out and rise 
substantial funding by the end of the first year of the company.” 
When asked about Opsona’s current presence within Ireland Prof. Mills stated “Opsona 
does not have a product or sell a product because it doesn’t have a licenced product. 
To get a licenced product you need to complete phase 3 clinical studies, Opsona was 
founded eleven years ago and is only in phase 2 now, so it is a long way off having a 




biotech, is outsource the production of the material for clinical trials to CMO’s. That’s 
what every small biotech company actually does – no one makes it in-house, it is 
always outsourced. Most of that outsourcing is not in Ireland, and generally they are 
sprinkled around the world as far a China – who do a service for a fee such as product 
development, manufacture, production and even clinical trials which are outsourced a 
lot of the time. Opsona did have 23 people at one stage which was the peak of where 
we were in terms of employment but the numbers now are much smaller than that 
because of the way we operate. Like every start-up biotech when it gets to phase 1 
they will in some ways downsize because they have done their research and now they 
are just trying to get their drug through clinical trials to go for either a trade sale or if 
they were lucky enough to get to phase 3 clinical trials – but to get through phase 3 
would be in excess of another €100 million, so most of the small biotech’s can take it to 
phase 3 and are acquired if they are luck enough.” 
Opsona Therapeutics can be describe as a successful start-up Biotech company as it 
has managed to secure significant amounts of funding and is progressing a drug 
through clinical trials. Enterprise Ireland did play a crucial role in the early start-up 
phase of the business, however Opsona’s overall impact on employment within the 
Irish Life Science sector is relatively small as the company has chosen to outsource 
virtually all elements manufacturing, development and clinical trials to contract 
company’s based outside Ireland. Although EI have invested a significant amount of 
time and finances in Opsona, the reality is that it will generate minimal employment 
within Ireland.  
One other key element highlighted by the Opsona story is the importance of having a 
CEO and management structure that has the business knowledge required to pitch for 
additional funding and navigate the company to a point where the product is 
marketable. By putting an “investible CEO” at the head of the company who was not a 
professor that founded the technology, Opsona effectively followed the University of 
Florida (UF) Sid Martin Biotechnology Incubator model which was discussed section 
2.6 (Breedlove 2014). Opsona removed the so called “fundamental flaw in strategy” by 
recruiting an experienced bio-manager and coupling that with “aggressive courting of 
venture capitalist” and this lead to the company becoming an attractive prospect for 
potential investors, this in turn meant the company was able to become financially 




4.6 TriMod Therapeutics Limited: 
 
Figure 14: TriMod Therapeutics Official Company Logo 
TriMod Therapeutics Limited is a start-up biopharmaceutical company founded in 2010 
based on a novel cancer treatment developed in Trinity College Dublin (TCD). The 
company’s sole product, “TriMoVac”, aimed to improve a patient’s immune repose and 
promote the destruction of viable cancer cell within the human body thus eradicating 
tumours. The idea to create TriMod Therapeutics originated when the two co-founders 
(Dr Jeremy Skillington and Professor Kingston Mills) were working for Opsona Limited. 
The company was supported by the Enterprise Ireland High Potential Start-up (HPSU) 
programme and successfully raised €750,000 in seed capital from the HPSU 
programme (Connolly 2012). This money was added to finance which was raised from 
an Angel investor to start the company.  
The founding member, Prof. Kingston Mills (who was also a founding member of 
Opsona Therapeutics) was interviewed about the creation of TriMod Therapeutics. 
Prof. Mills stated “the company has been mothballed at the moment”, “In the end it was 
funding. But we were trying to do something that was very complicated – it was a 
cancer therapy and we had two drugs that we were using in combination. A lot of the 
investors found it hard to get their head around the fact that we needed to have two 
drugs working together, it was too complicated for them. This was even compounded 
by the fact that we didn’t actually own either of the two drugs, we owned IP around the 
combination of the two drugs. Even though we had licencing deals in place to bring in 
the two drugs and use them, investors were nervous about the use of combinations. 
Also, we were at a very bad time during the middle of the recession and the investor 
appetite for risk was the lowest it had been for ten years. Therefore people were just 
not willing to put money into risky businesses.” “The Biotech sector is much more high 
risk-high return than the likes of IT or medical devices. Therefore a lot of the VC’s in 
Ireland at the time were going for lower risk low return investments because of the 
shaky nature of everything at the time. So, timing was not on our side as well.”  
When asked about TriMod’s involvement with EI Prof. Mills stated “The one issue with 
EI I have is that they give you some money in the first year or two and then they leave 




through and assist assistance with fund raising and the development of the company 
until it is actually going. We needed a relatively small amount of money to keep TriMod 
going until we could get to a proper A round, but EI, once they had given us the first lot 
of money that was it, they would not entertain anything else. I suppose they have their 
rules and their way of doing things, but we felt that they hadn’t followed through on their 
initial investment. That initial investment wasn’t insignificant and if they had given a bit 
more we might have been able to keep going.”  
When asked if he would consider revisiting TriMod in the future, Prof. Mills stated “Yes, 
we continue to push out IP. Universities have a very poor record of licencing IP and a 
lot of it sits in the University portfolios with nothing ever happening to it. The patent 
costs start to mount and in fact days ago I had a conversation with one of our in-house 
patent people asking me if I would drop a patent because even though the patent was 
granted they couldn’t see the potential for licencing it for big pharma. The avenue 
which is slightly easier or at least more doable is the start-up where you do it yourself 
and get it to a further stage. Large pharma won’t take on anything unless it has been 
through phase 1, so to get it through phase 1 you will not do that in academia so you 
have to do it through the start-up mechanism. That is why going the start-up route is 
almost the preferred round than trying to licence it to pharma from university.” 
TriMod is an example of a start-up that was founded on a promising technology but 
could not secure sufficient funding to make it to the next stage of development. EI did 
provide €750,000 of funding to the company but would not exceed that figure, even 
though this resulted in the company winding up operations. This is a potential area that 
needs to be addressed within the overall support mechanism, i.e. potentially 
companies could be reassessed and given additional funding (above the current EI 
limits) if it is deemed that they can successfully move on with the business.  
Having dealt with EI during the start-up of two separate companies, one a success 
(Opsona Limited) and one which has stalled in its development (TriMod Therapeutics), 
Prof. Mills is ideally placed to comment on the system as a whole and the role EI are 
playing.  He stated “If another Mark Heffernan was to walk in the door, I would be very 
tempted to restart TriMod because Mark was the catalyst for Opsona’s foundation. It 
would never have happened if it was not for him. He brought energy; he had the 
enthusiasm, ability and the experience to do it. Academics don’t have the time to do 
this unless they decide to do the very risky thing such as taking a leave of absence or 
cashing in your day job. To try and do this and keep your academic job going is very 




consuming – if you want to do it properly you need someone there doing it full time. 
That is why you need someone like Mark. He was fulltime CEO of the company from 
the very start and devoted all of his energy to the company. He brought fantastic 
experience and it just wouldn’t have happen without him.”  
One issue he identified is that there is a “very limited number of Mark Heffernan type 
people operating within the Biotech sector within Ireland – you could count on one 
hand the amount of people who have the wherewithal, the ability and the interest to go 
into something that is quite risky. The salary for a start-up CEO is pretty poor, and it is 
only when the company gets going will the CEO get properly paid. Therefore the CEO 
will have to give up a year or two of their life in terms of a salary. So there are very few 
people like that around. How do you entice them here – I just don’t know, it’s not easy. 
The US is full of people like that, if you go to California or the Boston area and look at 
the amount of start-ups there is far more. Obviously it is a much bigger country, but 
there just seems to be a different mentality in terms of risk taking and entrepreneurship. 
I think what Ireland needs to do is build its entrepreneurs – it is putting some things in 
place to help that, but by and large it has been poor. Using Mark as an example, he 
has a science PhD, has done an MBA and worked in business so he had the absolute 
perfect range of skills that were needed for a small biotech CEO. He understood the 
science, he understood money and he understood management. He also understood 
the business world and the language of how the talk to a VC. The language used when 
talking to a VC is not the same as the language I use when talking to my lab – that is 
something I learned very quickly and Mark brought that to the company immediately. 
That is what you need, people who understand the business side and understand the 
academic side.” 
This point raised by Prof. Mills again highlights the importance of having the correct 
management structure in place within a start-up Life Science company and reinforces 
the “lessons learned” that were identified during Penin & Wolff’s (2010) study of the 
elements needed for a successful start-up in the biotechnology sector. It could be 
argued that TriMod did possess two of the three key elements for a successful start-up 
as it had “Social Capital” due to the fact that it was within an ecosystem of other start-
ups and it did have “Physical Capital” in terms of a technology that was licenced and 
patient protected. But the company did not have the necessary “Human Capital” in the 
form of an entrepreneur with previous experience or a dual team of a scientific 
manager couples with an executive manager (Penin and Wolff, 2010). This ultimately 
made the company a less attractive investment proposition and was a primary cause 




4.7 Solvotrin Therapeutics Limited: 
 
 
Figure 15: Solvotrin Therapeutics Official Company Logo 
Solvotrin Therapeutics Limited is a pharmaceutical drug development company that 
originated in Trinity College Dublin and focuses on the chemical modification of existing 
well established pharmaceutical products to generate novel, patent protected chemical 
entities which offer improved efficacy and safety when compared to the existing drugs 
on the market (Solvotrin 2015).  The company has three main products in development 
which include a modified form of aspirin, a potent anti-cancer drug and a unique iron 
compound which has increased absorption capabilities.  
The company has setup its headquarters in Cork and also has offices in the Dublin 
school of pharmacy and pharmaceutical sciences in TCD. The co-founder and current 
Chief Technical Officer of Solvotrin Therapeutics, Professor John Gilmer, was 
interviewed about the company’s development and interactions with Enterprise Ireland. 
Prof. Gilmer stated, “the company started initially with EI funding and was then asked 
to participate in the business partners program, which was a program designed to 
match projects with commercial potential to experienced entrepreneurs. The 
experienced entrepreneurs were supposed to help to write a business plan, but my 
experienced entrepreneur decided to put his hand in his pocket and support the 
company himself”, this kick started the company. “The entrepreneur put in a substantial 
amount of money, EI also took a stake in the company and we were classified as a 
HPSU. We were also supported with an innovation partnership grant from EI”. Solvotrin 
were awarded the spinout of the year in 2010, they were given the use of the EI New 
York offices and introduced to a number of overseas contacts by EI.  
The company went onto meet with a large number of VC funds in an attempt to secure 
the finances needed to develop their primary Aspirin product and bring it to phase 1 
clinical trials. One large multinational pharmaceutical company, who were developing 
and trialing a drug with a similar therapeutic effect did show interest however due to 
issues outside Solvotrin’s control, the development of the product did not progress 
further. The company has now focused its efforts on developing its Iron product which 





One issue the company did see with the EI support system was that EI seemed to have 
a limit of €750,000 when it came to investing in a new company – which for a 
biotechnology company trying to develop a product to phase 1 studies is not a 
sufficient amount of capital. This is a similar issue which was faced by TriMod 
Therapeutics in its development. One recommendation made by Prof. Gilmer was “if a 
company can demonstrate that it has made a credible effort to deliver on a business 
plan, but ran into issues caused by circumstances beyond the company’s control, they 
should be eligible for additional finances if they can justify how they will be used.’’  
The story of TriMod and Solvotrin are quite similar in that they were both founded on 
novel scientific discoveries but could not secure the funding necessary to bring the 
product into clinical trials. If these companies were successful in getting their products 
to clinical trials they would most probably have gone down a similar road to Opsona, 
i.e. outsourcing many of the functions, as this is much more cost effective way of 
developing a product. If the product is successful in trials the likely next step would be 
acquisition of the technology by an existing multinational pharmaceutical company and 
the product would leave the country. Therefore one must question how much the Irish 
economy would gain in this process. Possibly EI were correct when they decided to 
limit the amount of funding in Solvotrin and TriMod, as a significant investment of Irish 
taxpayers money into a company which may not have a long-term future in the country 
could be deemed as an inappropriate use of public finances – this topic will be 











4.8 Oncomark Limited:  
 
Figure 16: Oncomark Official Company Logo 
Oncomark limited is a diagnostic company which is centered on the development and 
application of biomarker panels, particularly supporting oncology clinical decisions and 
drug development (Oncomark 2015) – the companies mission statement is “to use 
R&D collaboration as the driving force behind how we discover, develop and validate 
cancer diagnostic tests for our market facing partners.” The company was spun-out of 
UCD in 2007 and currently occupies space in the NovaUCD Belfield Innovation Park. 
The number of direct employees within the company has fluctuated between 10 – 20 
over the life of the business to date.  
One of the founding members of the company and current Chief Scientific officer, Prof. 
William Gallagher was interviewed about the formation of the business and the 
supports it leveraged. Prof. Gallagher stated, “Oncomark Ltd is a spin out company 
which I established with co-founder Steve Penny back in 2007 and really only got going 
2 years after that. Our strategy at the time was to put in some of our own seed money 
and we got some EI core support - a small amount of money to check out the market 
opportunity of the company. The company is focused in the area of medical diagnostics 
with a particular focus in the oncology sector and we were looking at a couple of 
different technologies from my academic lab as initial product opportunities. One of 
them did not pan out; it was originally a product from an EI proof of concept grant which 
didn’t really work as we couldn’t validate it. The second technology we successfully got 
a US and EU patent issued. It is an image analysis technology and we licenced that 
into Oncomark Ltd as a first product opportunity. In contrast to a lot of other companies, 
from an academic point of view, I have a good track record in availing of EU funds. 
Because the EU was quite supportive of small companies we decided to target EU 
funds directly instead of VC funding to really grow the company. For the first year and a 
half after incorporation we targeted a number of grants from the EU which kicked off in 
the middle of 2009. Since then we have gotten 8 grants from the EU totalling close to 
€5 million which would directly fund R&D activities within the company. We are an R&D 
heavy company which is a high risk area and a lot of the discoveries we find we cannot 




risky area for people to invest. We were fortunate to have that source of EU funding to 
do that activity.”  
When asked about the company’s interactions with EI, Prof. Gallagher stated “For the 
initial EI core grant, we participated in a campus company development program for 
about a year previous to the grant. It was a nine month program where they take 10 – 
12 new venture ideas and go through the process of trying to mature out the concept 
and so Steve and I participated in that. Steve was a mature student and had come from 
an investment funding background for about 15 years in London and Japan so he had 
lot of experience in business acumen. I obviously had a scientific background and so 
he went back and studied biotechnology in DCU and then he spent some time in my 
lab. Together we decided to push forward with the campus company development 
program to form a company in the oncology diagnostics space. As part of that process 
we became aware of the supports available from EI and we then applied for the core 
grant.”  
Apart from funding, Oncomark Ltd is not using any additional supports from EI, Prof. 
Gallagher stated “the initial support was for scoping out a market area for the 
technology and we subsequently have not gotten any EI support since then. We were 
teeing up some investment about two years ago, we were pushing forward an 
investment round and we had secured in principal EI funding of €250,000 but were not 
able to match that at that time from external investors. So you could say that we had 
good support in principal from EI but we haven’t subsequently gotten support or any 
direct funding as a company from EI to this point.” 
When asked about the next development stage for the company, Prof. Gallagher 
stated, “We need to go to the next step and get external investment from non-grant 
funded sources. That is the reason we have targeted a new CEO who has successfully 
commercialised two companies previously to the point of sale and so we needed 
someone who has that experience within the diagnostic industry. We have some 
experience but wouldn’t have a lot of industry experience. We needed someone with 
that experience who can drive the business forward and secure external investment. 
We will also pursue a grant funded strategy as well because that lessens the risk for 
external investors.  
At the moment EI are not directly involved in the company, “We would be at the fringes. 
In principal we fulfil the objectives of EI in terms of number of people and being a high 
performing start-up but we were kind of a different breed than what they are looking at. 




nature of Life Science takes a lot longer so we have slightly fallen out of that space. 
Every now and again we have been in contact with our point of contact within EI but no 
real concrete support at the moment.” “There is no real need for us to go to EI at the 
moment. Certainly if we go back and pursue another round of investment we would 
consider EI but they have a limited amount of money they can provide anyway so we 
may or may not decide if we are going to bring them on board.” 
One potential weakness identified with the EI supports was “they didn’t really suit our 
type of company; they’re probably used to dealing with IT companies who are quick 
turnaround with low potential overheads. Whereas Life Science companies are more of 
a slow burner and can take a while to mature.” The company had difficulties explaining 
the business concept to EI, “a business concept within biotech can be somewhat 
nebulous because you can be talking about something that is quite abstract so it is not 
like a piece of software. It was a potential promise of a new diagnostic but there is a 
long way to the validation of that technology. In the drug development space there can 
be 15 years from the proof of concept to actually delivering a product. So diagnostics 
can have a similar timeframe due to the validation of the product so it’s hard for people 
to grasp that.”  
In general the company had very good initial support from EI “On an indirect level, from 
an academic level, we have received a lot of support from EI. The two technologies 
that we did licence into the company were from EI funded sources so they were two 
tech development grants which allowed us to successfully bring the technology forward 
to a point of issuing patents and licencing the technology in the first and in the second 
we are still pending the patent. But from a company support point of view from EI there 
isn’t a huge amount. On the academic side when I was bidding for the EU grants we 
always sought very good support from EI for coordination support grants. These are 
small pots of money which help you bid for large EU grants which we were never 
turned down for and we were quite successful, above 50% for these programs. So from 
an academic point of view we got excellent support from EI. Once you step over into 
the company side we found that the supports, at least from our perspective, are quite a 
lot less or at least we haven’t availed of them or actively pushed on them.” 
The Oncomark development path is quite similar to that of Bioplastec in that they were 
founded on novel technology but the overall trajectory and time horizon on the 






4.9 Enterprise Ireland: 
 
Figure 17: Enterprise Ireland Official Logo 
In order to gain the EI perspective on the effectiveness of the supports they offer and to 
assess EI’s future vision for the area, an interview was completed with Brian O’Neill 
who is the current EI Manager of High Potential Start-Ups in the Industrial and Life 
Science Industry. When asked about EI’s current role when it comes to supporting 
start-up Irish Life Science companies, Mr O’Neill stated “We play a key role in the Irish 
Life Science industry really from a grass roots level, we are the largest investor in 
Europe and we take equity in just under 200 businesses per year, of which 
approximately 10 – 15% would be Life Science orientated. We would be the first port of 
call for any entrepreneur and we look to support any entrepreneur right the way 
through pre commercial activities. We apply a very significant amount of a financial 
budget into applied research with the specific purpose of seeding and funding 
technology which can either be licenced by existing industry or in terms of start-ups, IP 
and technology platforms that can be bundled together and spun out as start-up 
businesses.”  
“In addition to being a direct investor into businesses at an early stage we would 
probably be the friendliest investor (for want of a better word) that you would find and 
we review every proposition. We have a very specific technical and commercial due 
diligence system before we make any decision. We would really be the definite first 
port of call for many entrepreneurs and founders, in fact a lot of the work that we do is 
what an early stage founder would have to do but they would just not have thought 
about it. We have very significant expertise in terms of just the sheer volume and scale 
of start-ups that we are involved in and we have a keen interest in backing and 
developing technology companies that can have a differentiated platform on an 
international stage.”  
When asked about the types of companies that EI are looking for, Mr O’Neill stated, 
“Really we are interested in businesses which we refer to as High Potential, have 
international potential, have the ability to employ at least 10 people and have 
international market opportunity. We also fund the local enterprise offices throughout 
the country which gives us a reach right down to the grass roots of the early stage 




“I would describe our role in the process as critical and without us there would be 200 
business that would not be funded each year and really I think that in addition to being 
a direct investor in businesses we are also a fund of funds – as we are a limited partner 
in all of the seed investment programs throughout the entire country and at this point in 
time we have put in just short of €700 million in a seed investment scheme which is 
leveraged in about €1.3 billion in external finance. We have worked very closely with 
the private investment community to ensure that there are appropriate levels of capital 
available at all stages of development of business. We realise that different businesses 
are on different trajectories and will require different types of capital. More traditional 
businesses require traditional banking type facilities where as technology based and 
high risk companies need seed and venture types of funding. We would work closely 
with them to ensure that the private venture and our contributions ensue that there is 
sufficient capital available to support and follow on the investments that we make 
directly in our businesses at an early stage.” 
When asked about how EI identifies potential start-ups and interacts with them Mr 
O’Neill stated “I think that any entrepreneur within the system will come to EI at some 
point”, “we get about 1000 enquiries a year, of which we finance about 450, of which 
200 are equity based investments, of which approximately 100 are considered the 
crème de la crème high potential start-ups as we call them. We get a lot of people 
coming in our doors and we try to provide as much support to them as possible. We 
equally go looking for opportunities throughout the country as we have a regional 
spread with offices throughout Ireland. We fund the local enterprise offices which have 
an even wider reach then we do to the more grass route level opportunities and we 
want businesses to come in our doors.” One of the key roles of EI is to identify 
opportunities “which really have international potential and ensure that there is the right 
team, the right financing structure that can support a viable business proposition that 
can be funded by the private market – that is something that is essential, we need to 
see somebody that can obtain other financial supports other than us.” 
Securing the finance required to kick-start the business was a key EI support utilised by 
all of the start-ups interviewed during the course of this study.  When asked about this 
element of the EI supports system, Mr O’Neill stated “we do about 100 competitive start 
funds per year and that’s where we literally go to people who have opportunities in a 
specific field, maybe graduates, female entrepreneurs, overseas entrepreneurs, 
opportunities in aviation and manufacturing which we did last year. Also we would have 
general calls which we would run maybe 6 – 7 times per year. Literally we would do 




ideas to come in the door and if successful they put in €5000 and we will put in €50,000 
so the business can be funded quickly and cheaply so that they can prove their 
business model in as lean a manor as possible.”  
When asked about how EI manage the initial interactions with a potential start – up 
company Mr’ O Neill stated “Our first port of call is to discuss the business idea, give 
them a mentor, give them €15,000 feasibility funding just to build an investor ready 
proposition, a business plan and scope out their opportunity. They may get competitive 
start funding, they may go to the accelerator program such as the new frontiers 
program where we put €15,000 tax free for six months”. The company may then “apply 
for our competitive start fund, which would give them €50,000 and then they would 
come back for our HPSU money which is in the €100’s of thousands.” 
Another issue identified when interviewing companies who started with EI support was 
the fact that there was a lack of experienced mentors within their specific field. When 
asked how this mentor pool is created Mr O’Neill stated “We are always approached 
and are always looking for high quality experienced mentors across all sectors and 
people are always willing to give back. We are always approached by people who are 
looking for potential opportunities as well as looking to give back to other entrepreneurs 
and relay their experience to others. We have built a very significant panel of mentors 
that we vet and we will pull mentors from all areas including finance, product 
development, overseas development etc. to give their expertise. We will cross 
reference our database and let companies pick who they want.” 
“We also run a business partners program that aims to help technology spin outs from 
third level institutions. We would get people with a very significant track record, 
financial wherewithal and good experience and bring technology with commercial 
potential to their interest so that they can bundle it together and form a start-up 
themselves. Not alone do we bring mentors to existing businesses but we bring people 
to form new businesses.”  
Mentoring is an area that EI are currently seeking to develop “given the sheer volume 
of businesses we work with now, we are undergoing a significant change program 
where we are putting together an accelerate program so that we wrap around all of the 
business we are investing in and we will provide founders networks, group coaching, 
facilitative group coaching, business masterclasses, overseas sales and marketing 
support, market access support and we will regularly meet with our clients who 
understand the challenges they are facing and to ensure they are getting the supports 




they are key to ensuring that companies are identifying appropriate partners in 
appropriate geographic areas so they can get to markets faster, quicker and gain 
market traction. We hope to have this accelerator program up and running in October.” 
Once the start-up company has made it through the initial development stages and 
proven that they have a potentially viable business, many then struggle to get the 
necessary finance either from traditional financing mechanisms, VC funds, angel 
investors or government bodies required to bring the business to the next level – 
TriMod Therapeutics and Solvotrin Therapeutics are examples of this situation. This 
may be linked to the fact that the time-to-market for biotech/pharmaceutical products is 
very long and very risky in comparison to other sectors where EI are actively investing 
e.g. IT. When asked about the process of allocating additional finance to Life Science 
start-ups and helping them to find other sources of external finance on the open market 
Mr O’Neill stated “the overriding determinant to how much we invest in the business is 
the job creation potential for the business. Typically while biotech or Life Science 
businesses employ less people, the economic multiplier of those businesses operating 
in the economy is very substantial, they spend a lot in the economy, they employ very 
high value added people, they are typically employing very highly educated graduates, 
their average salaries are higher, their spend is higher, their research intensive, they 
use a lot of ancillary service providers. So while they may not have a very significant 
number of direct employees, it balances out in the overall context. The biggest 
challenge businesses face is being able to raise sufficient private sector capital to drive 
forward opportunities and that’s why we have invested so significantly in our seed 
venture programs.”  
During the course of the interviews with companies who used EI funding, a number 
mentioned “milestones” which EI set as part of the funding deal. When asked about 
these milestones Mr O’Neill stated “we are not that different than most investors but we 
are interested in the development of the business for different reasons, we are not so 
much interested in commercial return on the business, we are more interested in the 
economic return on the business so we often transfer money along pre-determined 
milestones – either technical or commercial which are case specific and case 
dependent as it should be because every business is different and every business 
requires different interventions at different times. For example, we may release 
€200,000 right now and not release another €100,000 depending on the next technical 





One of the metrics EI uses to measure its performance within a given sector is the 
number of companies it supports and funds within a given year, this was identified as a 
possible issue with the Irish system when interviewing founders of companies who 
were successful in securing some initial investment from EI but could not obtain any 
follow up investment. One potential solution to this issue would be to reduce the 
number of companies funded by EI and give more money to companies who have a 
higher probability of delivering a successful business.  When asked if the EI goal is to 
increase the overall number of start-ups or if it is to stick to a finite number and try to 
increase the quality of the companies Mr O’Neill stated “five years ago we were doing 
65 businesses a year, now we are doing over 100 HPSU’s and 100 competitive start 
funds - so we have gone from 65 to 200 in the space of five years. Our three year 
target is to do 550 start-ups, 300 of which are high potential and 250 of which are 
competitive start funds so certainly for this year and next year the run rate will be 100 
HPSU’s per year. That number is a real challenge because we are doing twice what 
some of our competitor economies are doing - this represents a resource challenge as 
our business development officers are being asked to do a lot more with less people.”  
“In the Life Science space we have a portfolio of approximately 350 businesses and 
our economic data on them have shown that our job creation and exports from these 
companies have been growing year on year. We have more value added business, in 
that they have moved up the value chain from being commodity suppliers to own brand 
developers to product development companies to therapeutic businesses, to diagnostic 
businesses to point of care business. We have really seen an explosion in terms of the 
Life Science start up community because when there was a wider down turn, a lot of 
investors started looking closely for the returns that were available and the quality of 
the businesses that are being set up in Ireland. So certainly our indigenous Life 
Science company base is highly innovative, highly dynamic, highly globalised and 
actually a great place to work. We have some fantastic businesses operating in the 
country that are global leaders.” 
When asked about how the EI policy and future strategy is set and if they assess what 
is happening in other geographic areas of the world when setting the Irish policy Mr 
O’Neill stated “in terms of benchmarking we always look at comparable size economies 
that are high tech – so we look to Finland, Denmark etcetera. In terms of our output we 
are twice the output of these economies. Denmark does about 49 start-ups per year, 
whereas we are doing over 100 high potential ones per year and up to 200 which we 
have put equity in. We know already that we are the largest investor in Europe from a 




geographies and pick the best interventions that we see. I have to say that it’s typically 
the other way around; I spend a lot of my time working with other countries.”  “We are 
at this as a country for about 35 years, so we have actually have a very well developed 
industrial development system but certainly we are always looking for ways to improve 
and to ensure that we remain relevant to businesses and business sectors as they 
develop and evolve.” 
As EI have interacted with 100’s of Irish start-ups within the Life Science sector Mr 
O’Neill was asked if there are any common issues identified within this sector; “Each 
company typically has its own specific set of challenges, but if you want to be general, I 
think we have a lot of learnings – we run a program specifically tailored to a subset of 
HPSU with the highest potential which focuses on building a team and management 
capabilities. You can have a mediocre idea with a fantastic leadership and 
management team that will go a long way further than a brilliant idea with poor 
execution. Leadership and management will make a bit of a difference.”  
Also “sales & marketing is a big challenge for companies as they really need to think 
about internalising from the get go because of the very fact that we are an island. 
Product market fit is something that is a challenge to a lot of businesses to ensure that 
they are investing and building a product or service that is actually required or wanted 
by the market and that the market is willing to pay for, and it is in a format that the 
market is willing to pay for. That is particularly true in the Life Science sector as we are 
seeing large companies becoming less willing to invest in early stages and more likely 
to wait until they’re less risky and pay more for them. This means that there is an awful 
lot of impact on the type of capital and the length of time that investors have to carry 
investments before they can actually gain significant traction in a particular market.” 
Most companies “that went through our accelerated growth program (approximately 60 
– 70%) have pivoted which is a fancy way of saying they have tweaked or trailed or 
changed slightly their proposition. Initially they may have thought they would get 
traction in market A but they have found that if you go after A, B and C it is a more 
powerful proposition for the company. That is just the nature of business and I think the 
quicker we can provide a market feedback system to people the better, so in that 
regard we do a lot of work such as act for silicon valley in the US and in the UK, we do 
the same throughout all of our key geographic areas for our start-ups and we ensure 
that they are familiar with the local market, local processes and any issues that may 
arise. The businesses can be faced with significant technical, regulatory, financial and 





In terms of future goals and challenges for EI in the Life Science sector, Mr O’Neill 
stated that the first goal “will be ensuring that there are sufficient types of capital 
available, which there are right now, but really bringing business to scale is the next 
frontier for us. We also see very exciting businesses that have true global potential 
selling before they really need to sell; this is possibly due to risk aversion or more 
specific issues.” “My focus is scale; also there are market opportunities that are going 
to open up in Asia. These are markets that are different to do business in but really with 
the explosion in the number of middle income consumer spending, we expect to see 
very significant opportunity and that is why we are increasingly opening offices in China 
and in the Middle East and Asian economies.”  
As a closing comment about the current state of the Irish Life Science sector Mr O’Neill 
stated “Life Science businesses have to be global from the get go, global systems and 
the macroeconomic environment drivers also impact indigenous businesses.  While 
most talk about consolidation of the larger MNE’s, the flip side to that is that there is an 
insatiable desire amongst the global multinational community for next generation 
technology and opportunity. That really creates an opportunity for economies who are 
investing in the early stage high potential businesses which provide the next generation 
technology who then become international beacons for innovation. It actually creates 
great opportunity, so I actually think that there has never been a better time to set up 
an early stage Life Science business because you have more interest from the global 
market than you’ve ever had before”. “No one country, no one company, no one 
economy can have a monopoly on the Life Science space because it is so complex, is 
multi-disciplinary, involves more stake holders than it has ever before and it involves 
more disciplines than ever before. That puts economies like Ireland and those that 
invest in, and continue to invest in, the research that underpins these businesses and 
follow it up with early stage seed funding, incubation and venturing of businesses in a 
very strong position as global MNE’s and the general global community are 
increasingly looking for new products and services to meet medical and clinical needs 
of society.” 
Based on the information publically available on EI and the findings of the interview 
with Mr. Brian O’Neill it is clear that EI are aware of the challenges and opportunities 
which exist in the Irish Life Science sector. They are actively seeking to address the 
key areas of funding, business development & mentoring and the internationalisation of 
Irish Life Science companies through the implementation of a number of mechanisms. 




4.10 Summary of Research Findings:  
The key measure of “success” for the companies which were assessed during this 
research is the level of employment generated by the business; this success indicator 
was selected because it is the primary goal of the Enterprise Ireland support 
mechanisms. One of the key EI criteria for a High Potential Start-up Company is that it 
must be capable of creating at least 10 jobs in Ireland - therefore for the purposes of 
this dissertation, any company which created 10 or more new jobs in the Irish Life 
Science sector was deemed a “successful start-up”.  
Table 3 gives an overview of the research findings by presenting the primary EI 
supports used by each company, the number of jobs created and a current status of 
the business.  
Four of the seven companies researched were classified as “successful start-ups” and 
a total of 145 new jobs in the Irish Life Science sector were created across all seven 
businesses. The over-all EI funding provided to these companies was in the region of 
€3 million (this is an estimated figure as some companies did not wish to disclose 
financial details); which translates to approximately €21,000 per job created (excluding 
the cost of providing non-financial EI supports). This is a strong return on the EI 
investment when one considers that the current average salary in the Life Science 
sector is far in excess of the average industrial wage of €32,500 (Brightwater 2015).  
The data collected during the course of this dissertation generated the information 
needed to address the primary research question that was discussed in Section 1.4 as 
the EI supports utilised by each company were identified and the effectiveness of the 
supports from the perspective of the company founders was determined. The interview 
with the EI HPSU Manager also generated the data required to gain an understanding 
of the support bodies’ primary objectives, its strategy for the Life Science sector and 
what actions it is taking to address the problems the sector is facing.      
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Chapter 5: Discussion 
 
5.1  Introduction:  
Although all seven companies researched as part of this study operate in very different 
areas of the Irish Life Science sector, a number of similarities were identified with 
respect to their interactions with Enterprise Ireland and how the companies used the EI 
supports offered to them. In all cases the company founders were very positive about 
their initial interactions with EI; all accepted seed funding to explore the potential of 
their business, all were provided with business mentors and all were put in contact with 
experienced business partners. In some cases these business contacts became large 
investors and fundamental parts of the management structure within the company. In 
most circumstances the company founders acknowledged that they would not have 
been able to make it through the early development stages without the supports 
provided by EI.  
 
5.2  Interactions with Enterprise Ireland:  
Although the initial interactions with EI were similar for all seven companies, their 
development stories began to diverge at approximately the one year mark and they can 
be classified into three distinct groups based on their experience and interactions with 
Enterprise Ireland;  
 
1. Financially Self Sufficient:  
APC, Oxymem and Opsona quickly became financially self-sufficient by either 
generating cash flow through growing their customer base or by raising 
significant investment from VC funds and angel investors. This allowed EI to 
effectively take a back seat in the company’s development and focus its energy 
on the identification of new opportunities. In terms of the number of jobs created 
relative to the amount of EI funding and support required these companies are 
excellent examples of how an effective and well-managed support function can 
have a significant economic impact. Between the three companies they have 
created over 100 new jobs (the majority of which are highly skilled) and in the 
case of APC and Oxymem, these companies look set to have a presence within 
Ireland for many years to come. This is the space where the current EI support 
mechanisms are most effective i.e. they give a promising young company some 




to develop to a point where it can support itself. This is the true value of EI to 
the Irish economy and these are types of companies EI are actively seeking. 
The progress of these companies also highlights just how critical external 
finances are to the development of the business. 
 
2. Conflicting Vision for the Business : 
In the case of Bioplastec and Oncomark, there was a fundamental 
misalignment between the EI vision for company’s development and the 
founder’s vision. The source of this misalignment was the length of time it would 
take to develop the companies to a point where they saleable products. This is 
particularly true for Bioplastec and led to its founder being reluctant to engage 
fully with the EI. The development (or lack thereof) of these two companies 
does not necessarily reflect entirely negatively on the EI support process as the 
same supports were made available to both companies in their early 
development stages and these were utilised to grow the businesses to a point. 
Also, these supports are still available to the companies and both CEO’s 
regularly “check-in” with EI in order to maintain an active working relationship.  
These two cases highlight the importance of “fit” between the start-up and the 
support systems in terms of vision for the business and development time lines. 
EI have a clear vision and criteria for what defines a HPSU; although both of 
these companies were classified as HPSU’s initially, they are yet to achieve 
their full potential. Both companies expressed an interest in reengaging with EI 
at some point in the future if required.  
 
3. Promising Company, Insufficient Funding: 
TriMod and to some extent Solvotrin can be classified as companies who have 
very promising medicinal products but to date have not secured the funds 
required to bring the projects to the next level – this is a direct contrast to the 
three companies that became financially self-sufficient within the first year. One 
issue which was raised by the founders of both companies was that EI seemed 
to have strict internal rules on the level of funding provided to each company 
(capped at €750,000 based on the experience of the two companies). Both 
companies recommended that the EI rules should be made more flexible and 
companies who have a potentially viable product should be eligible for 
additional funding. However whether or not EI should invest large sums of 




the core of what EI is looking to achieve within the Irish economy (this issue will 
be discussed further in section 5.3). 
 
5.3  The Role of Enterprise Ireland: 
Some company founders who were interviewed during the course of this study were of 
the opinion that the role of EI should be to identify potentially high value Life Science 
innovations and support these innovations to the point where the technology is 
saleable; they accepted that this strategy is high risk but there would be potentially high 
financial returns for EI if successful. However, the findings of this study clearly show 
that EI are not in the business of making high risk investments with taxpayer’s money 
in order to make a financial return. In the interview with Mr O’Neill he stated that EI’s 
primary focus is not on a commercial return on their investment, rather they are looking 
for an economic return in the form of job creation.  
When one looks at the EI investment strategy in this light it makes perfect sense for the 
support body to distribute their budget across as many start-up companies as possible 
and to grow the level of R&D activity which in turn creates high value jobs. The one 
caveat to this strategy is that the potential start-up companies must pass the due 
diligence processes which EI have in place – this is a prudent and effective way of 
managing EI’s resources. Also measuring EI’s annual performance based on the 
overall number of companies started is an appropriate metric for gauging their success 
as it keeps the organisation focused on this key area. However EI could benefit from 
the introduction of additional more sophisticated measures, such as the ones used by 
the University of Florida Incubator (discussed in section 2.6) which included metrics on 
company survival rates, total funding, regulatory progress, patents, corporate 
partnerships, acquisitions, IPO’s, number of products to market and number of local 
jobs created (Breedlove 2014).  
 
5.4  EI Strategy:  
An assessment of the “types” of Life Science companies supported by EI was 
completed based on the findings of this study in order to guage the effectiveness of the 
support mechanism. The majority of EI supported companies studied (with the 
exception of Oxymem and APC Ltd, who have products that do not require the same 
level of regulatory approval) are active in the Lead Selection, Pre-Clinical, Phase I and 




current EI supports are delivering on their objective of growing the level start-ups based 
on indigenous R&D and that EI strategy is attempting provide an effective system 
where companies can develop their technology to a “proof of concept” stage. This is a 
strategy supported by PharmaChemical Ireland who (as stated previously) are 
adamant that “If the industry in Ireland is to survive and prosper, it needs to remain 
strategically relevant – this means investment in the development of new technologies 
such as biotechnology”, refer to figure 2 for an overview of the process (Moran 2013).  
Once EI have helped the company reach a stage where it is ready to pitch for 
additional third party funding the supports reduce and it is expected that the company 
should then start to become self-sufficient. If the business is genuinely viable and there 
is a market for what it is offering then it will more than likely be successful in obtaining 
the required funding on the open market – as was the case with Opsona Therapeutics 
and Oxymem Limited. The VC funds and angel investors who are active in the global 
Life Science sector are extremely experienced when it comes to investing in start-ups 
and have a wealth of expertise which is used to assess the feasibility of each business. 
Arguably they are far better placed then EI when it comes to assessing the potential 
financial return on a business investment. 
If a start-up company is not successful in securing VC funding on the open market to 
develop their product further, then one could conclude that EI are correct to not allocate 
additional funds to that business. Instead these funds should be diverted to a new start-
up which at a minimum will create new R&D employment opportunities within the local 
Irish sector.  
 
5.5  Importance of Leadership:  
Another key element which was identified during this study was the importance of 
installing an effective management and leadership structure within the company. 
Ideally this management structure should be put in place early (prior to spinning out the 
business) as it provides a platform upon which the company can grow. All of the 
successful companies reviewed in this study had a strong CEO who drove a clear 
vision for the company that was communicated effectively to potential investors – 
Oxymem Ltd is a prime example as they had a long term vision for the business from 
its very inception. Having this strong base in place from an early stage was a key 
enabler for the growth of the business and was critical when it came to securing 




EI can play a vital role in the creation of strong leadership teams within Irish Life 
Science start-ups through the provision of appropriately experienced business mentors 
who can guide the business in the early stages and even become part of the 
management team – this was effective in the case of Oxymem Ltd. However, this study 
has highlighted that EI need to do more work on their offerings in this area and it needs 
to grow the level of expertise within its mentor pool. This is a point EI did acknowledge 




Chapter 6: Conclusions 
 
6.1 Introduction:  
This study set out to assess a range of Irish start-up companies in the Life Science 
sector, determine how they are using the Enterprise Ireland supports available and if 
these support structures are meeting the needs of each company. The development 
paths taken by each of the seven companies’ studied was very different and each 
company used the EI supports to varying degrees depending on their business model. 
All companies studied, received the same initial supports from EI in the form of seed 
funding and coaching / mentoring which facilitated the initial growth within the business. 
One theme that was identified in all cases was that the current Irish system is effective 
at funnelling Life Science start-ups into the EI support system; this indicates that the 
current EI network throughout the country is an appropriate model for identifying high 
potential companies. Based on the findings from the interviews it was clear that all 
company founders were aware of the supports available from Enterprise Ireland and 
engaged with the support system at a very early stage in their business development.   
 
6.2  Implications and Recommendations:  
A critical finding from this study was that the companies supported by EI did generate 
new employment within the Life Science sector which met the core objectives of 
Enterprise Ireland. Approximately 145 highly skilled Life Science jobs were created 
across the development lifecycles of the seven companies studied; this is equivalent to 
a medium size “Big Pharma” manufacturing facility and supports the hypothesis that a 
vibrant indigenous Life Science sector can create enough employment within Ireland to 
reduce the sectors dependence on foreign multinationals. Job creation in this area also 
has a significant multiplier effect for the broader economy as it has been shown to 
stimulate jobs in support services – a study completed by the University of 
Massachusetts estimated that between 3.6 - 5 additional jobs are generated from the 
creation of every 1 direct Life Sciences job (Deval L 2008). 
The findings of this study did identify two key areas where the current system is in need 
of development and the following recommendations have been made; 
1. Support for Securing External Finances: 
Additional support is required when it comes to helping Irish companies secure 
funding on the open market to further develop their businesses. The majority of 




Ireland are not meeting their needs and they had to seek finance outside the 
country. EI may not have the ability to improve the local EI funds in Ireland, but 
the support body could use its extensive global network to link Irish companies 
with appropriate funds that would be more likely to invest in Life Science start-
ups. This may improve the success rates of Irish start-ups.  
 
2. Mentoring System Development:  
The provision of business mentors with the necessary experience and 
capabilities required to guide relatively inexperienced academic entrepreneurs 
in the business world is another area where EI needs to develop its offering. 
The study completed by Shiri M. Breznitz (2013) (discussed in section 2.2) on 
why the Israeli Life Science cluster remains unsustainable identified that the 
Israeli sector “is suffering from a lack of knowledge of later stage Life Science 
production” (Breznitz 2013). Ireland has developed an extensive amount of 
expertise within this area due to the presence of multinational pharmaceutical 
companies in the country for over 50 years. Because of this, Ireland possesses 
a significant pool of business experts in all areas of Life Science company 
development. EI should look to this pool of people when attempting to 
strengthen the mentor program.  
EI have recognised these two areas as opportunities to develop their current offerings 
and are currently addressing them through the implementation of a number of 
initiatives. The impact of these initiatives may form the basis of further research within 
the area of Life Science start-ups.   
Another area where the Irish system could grow is in the creation of links between 
indigenous companies which may lead to advantages such as collaborations, 
economies of scale and the formation of clusters of companies who can support each 
other as opposed to relying on EI. Although this topic of cluster formation was outside 
the scope of this dissertation and was not specifically discussed during the collection of 
primary research, the cluster model of Life Science development has been researched 
heavily (as described in section 2.2) and the creation of Life Science clusters within 
Ireland could also be an area for further research in the future. At the moment one 





6.3  Contributions and Limitations of this Research: 
This research achieved its primary objective and identified a number of areas where 
the current support system is meeting the needs of start-up Life Science companies 
and areas where the system requires further development. The level of employment 
created from the seven companies profiled in this study supports the hypothesis that 
development within the indigenous Irish Life Science sector has the ability to generate 
significant levels of high value employment and can reduce the sectors dependency on 
foreign multinational companies. This study also found that Enterprise Ireland are 
aware of these issues facing Irish Life Science start-ups and are actively seeking to 
address them through the introduction of new support mechanisms and initiatives.  
This dissertation could be described as “exploratory research” within the area of Life 
Science start-up development, therefore one expected limitation of this report is that 
the sample size of companies studied is relatively small when compared to the number 
of companies that EI support within the Life Science sector. The findings of this 
exploratory research could be used to develop further studies that target a larger 
sample size of companies – these additional studies could then verify (or challenge) 
the findings of this dissertation.  This verification would be required in order to support 
the recommendations made prior to the implementation of any actions.  
 
6.4  Final Conclusions and Reflections:  
In conclusion, the ecosystem within the Irish Life Science sector created by the 
Enterprise Ireland is conducive to the formation of new businesses and as a result has 
the potential to create a sizeable level of high skilled new employment. This indigenous 
employment will never eliminate Ireland’s dependence on foreign multinational Life 
Science corporations, but it may prove to be an effective protection against global 
market fluctuations such as large scale mergers & acquisitions and the movement of 
bulk production to geographic areas which have a lower cost base. EI’s strategy of 
focusing on increasing the number of start-ups year-on-year is an effective way of 
generating as much economic activity from their resources as possible and 
improvements in the provision of funding and mentoring can only make for a stronger 
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Appendix 1: Interview transcript from Enterprise Ireland interview. 
 
Brian O’Neill - Enterprise Ireland Manager of Life Sciences:  
Q: Can you give an overview of the role EI plays in supporting Irish Life Science 
Companies?  
“We play a key role in the Irish life science industry really from a grass roots level, we 
are the largest investor in Europe and we take equity in just under 200 businesses per 
year, of which approximately 10 – 15% would be life science orientated. Really we 
would be the first port of call for any entrepreneur and we look to support any 
entrepreneur right the way through pre commercial activities. We apply a very 
significant amount of our financial budget into applied research with the specific 
purpose of seeding and funding technology which can be either licenced by existing 
industry or in terms of start-ups IP and technology platforms that can be bundled 
together and spun out as start-up businesses.” 
“In addition to being a direct investor into businesses at an early stage we would 
probably be the friendliest investor (for want of a better word) that you would find and 
we review every proposition. We have to a very specific technical and commercial due 
diligence system before we make any decision. We would really be the definite first 
port of call for many entrepreneurs and founders, in fact a lot of the work that we do is 
what an early stage founder would have to do but they would just not have thought 
about it. We have very significant expertise in terms of just the sheer volume and scale 
of start-up that we are involved in and we have a keen interest in backing and 
developing technology companies that can have a differentiated platform on an 
international stage.” 
 
Q: What types of companies are EI looking for?  
 “We are interested in businesses which we refer to as High Potential, have 
international potential, have the ability to employ at least 10 people and have 
international market opportunity. We also fund the local enterprise offices throughout 
the country which gives us a reach right down to the grass roots of the early stage 
entrepreneurial activity within Ireland.” 
“I would describe our role in the process as critical and without us there would be 200 




a direct investor in businesses we are also a fund of funds – as we are a limited partner 
in all of the seed investment programs throughout the entire country and at this point in 
time we have just put in short of €700 million in seed investment scheme which is 
leveraged in about €1.3 billion in external finance. We have worked very closely with 
the private investment community to ensure that there appropriate levels of capital 
available at all stages of development of business. We realise that different businesses 
are on different trajectories and will require different types of capital. More traditional 
businesses require traditional banking type facilities where as technology based and 
high risk companies need seed and venture types of funding. We would work closely 
with them to ensure that the private venture and our contributions ensue that there is 
sufficient capital available to support and follow on the investments that we make 
directly in our businesses at an early stage.” 
 
Q: Do businesses typically approach EI or does EI actively seek new 
opportunities?  
“It’s a mix of both; I think that any entrepreneur within the system will come to EI at 
some point. Secondly I think that we get about 1000 enquiries a year of which we 
finance about 450 of which 200 are equity based investments of which approximately 
100 are considered the cram-de-la cram high potential start-ups as we call them. We 
get a lot of people coming in our doors and we try to provide as much support to them 
as possible. We equally go looking for opportunities throughout the country as we have 
a regional spread with offices throughout Ireland. We fund the local enterprise offices 
which even have a wider reach to the more grass route level opportunities and we want 
businesses to come in our doors. And we want people with ideas and really the trick is 
identifying the opportunities which really have international potential and ensure that 
there is the right team, the right financing structure that can support a viable business 
proposition that can be funded by the private market – that is something that is 
essential, we need to see somebody that can obtain other financial supports other than 
us.”  
“We have a variety of programs at different stages, New Frontiers which is held out of 
our institutes through the country where you would have early stage entrepreneurs who 
are put on accelerator programs to help them build and develop their proposition. 
Similarly we work closely with the BIC (business innovation centres), Dublin BIC, Cork 
BIC, West BIC in terms of helping the system build propositions on our behalf and with 




mechanisms. Certainly we do directly go to the markets. For an example, we do about 
100 competitive start funds per year and that’s where we literally go to people who 
have opportunities in a specific field, maybe graduates, female entrepreneurs, 
overseas entrepreneurs or opportunities in aviation and manufacturing which we did 
last year. Also we would have general calls which we would run maybe 6 – 7 times per 
year so literally we would do about 8 calls with a mix of both targeted and open looking 
for entrepreneurs with ideas to come in the door and if successful they put in €5000 
and we will put in €50,000 so the business can be funded quickly and cheaply so that 
they can prove their business model in as lean a manor as possible.” 
  
Q: Would that be stage one of the interaction, looking at the business concept?  
“No, the first stage of interaction (we get about 1000 enquiries a year), someone would 
ring up or come to us with a business idea and we take it from there. Our first port of 
call is to discuss the business idea, give them a mentor and give them €15,000 
feasibility funding just to build an investor ready proposition, a business plan, and 
scope out their opportunity. They may get competitive start funding or they may go on 
to the accelerator program such as the new frontiers program where we put €15,000 
tax free for six months.” 
“We have a variety of different inventions and they may apply for our competitive start 
fund, which would give them €50,000 and then they would come back for HPSU money 
which is in the €100’s of thousands. There is a gambit of ways in which entrepreneurs 
and early stage businesses can work with us and we have tools and instruments which 
reflect the makeup of the industry that is out there so that business that have different 
trajectories and business which are in different sectors have supports which are 
appropriate to their needs.” 
 
Q: How do you build the network of mentors and assign them to various 
companies?  
“We are always approached and are always looking for high quality experienced 
mentors across all sectors and people are always willing to give back. We are always 
approached by people who are looking for potential opportunities as well as looking to 
give back to other entrepreneurs and relay their experience to others. We have built a 
very significant panel of mentors that we vet and we will pull mentors from all areas 




expertise. We will cross reference our database and let companies pick who they 
want.”  
“We also run a business partners program to help technology spin outs from third level 
institutions where we would bring people with very significant track record, financial 
wherewithal and good experience and take technology with commercial potential to 
their interest so that they can bundle it together and form a start-up themselves. Not 
alone do we bring mentors to existing businesses but we bring people to form new 
businesses.” 
 
Q: Who mentors the business?  
“When the businesses come in the door they will be assigned a senior business 
development advisor to work with them. Given the sheer volume of businesses we 
work with now we are undergoing a significant change program where we are putting 
together a accelerate program so that we wrap around all of the business we are 
investing in and we will provide founders networks, group coaching, facilitative group 
coaching, business masterclasses, overseas sales and marketing support and market 
access support. We will regularly meet with our clients who understand the challenges 
they are facing and to ensure they are getting the supports they need when they are 
required. We have 33 overseas offices at the moment and they are key in ensuring that 
companies are identifying appropriate partners in appropriate geographies so they can 
get to markets faster, quicker, earlier and gain market traction earlier. We hope to have 
this accelerator program up and running in October. So, that is just an addition to our 
work.” 
 
Q: The time to market for the product can be quite lengthy and you don’t see a 
return in the short term – is this issue when allocating funding to companies?  
“No, the overriding determinant to how much we invest in the business is the job 
creation potential for the business. Typically while biotech or life science businesses 
employ less people, the economic multiplier of those businesses operating in the 
economy is very substantial. They spend a lot in the economy, they employ very high 
value added people, they are typically employing very highly educated graduates, there 
average salaries are higher, their spend is higher, their research intensive and they use 
a lot of ancillary service providers. So while they may not have a very significant 




challenge business face is being able to raise sufficient private sector capital to drive 
forward opportunities and that’s why we have invested so significantly in our seed 
venture programs.”  
 
Q: When you do identify a HPSU and make a significant investment, do you set 
out milestones for the company to achieve?  
Yes, we are not that different than most investors but we are interested in the 
development of the business for different reasons, we are not so much interested in 
commercial return on the business, we are more interested in the economic return on 
the business so we often transfer money along pre-determined milestones – either 
technical or commercial which are case specific and case dependent as it should be 
because every business is different and every business requires different interventions 
at different times. For example, we may release €200,000 right now and not release 
another €100,000 depending on the next technical or commercial milestone which is 
imperative to the longer term growth of that particular business.” 
 
Q: How do you set the EI policy and strategy, do you look at what other 
geographic areas are doing? 
“Absolutely, in terms of benchmarking we always look at comparable size economies 
that are high tech – so we look to Finland, Denmark excreta. In terms of our output, we 
have twice the output of these economies. Denmark does about 49 start-ups per year, 
whereas we are doing over 100 high potential ones per year and up to 200 which we 
have put equity in. We know already that we are the largest investor in Europe from a 
deals basis. But we very much keep a close eye on what’s going on in individual 
geographies and pick the best interventions that we see. I have to say that it’s typically 
the other way around; I spend a lot of my time working with other countries. Just 
yesterday a colleague of mine was doing some work with the Belgian government 
because they wanted to benchmark what we do in Ireland. We are at this as a country 
for about 35 years, so we actually have a very well developed industrial development 
system; but certainly we are always looking for ways to improve and to ensure that we 





Q: When supporting HPSU’s are there any common difficulties you face in 
supporting different companies, or is it company specific?  
“Each company typically has its own specific set of challenges, but if you want to be 
general, I think we have a lot of learnings. We run a program specifically tailored to a 
subset of HPSU with the highest potential which focuses on building a team and 
management capabilities. You can have a mediocre idea with a fantastic leadership 
and management team that will go a long way further than a brilliant idea with poor 
execution. So, leadership and management will make a bit difference.”  
“Also, sales & marketing is a big challenge for companies and they really need to think 
about internalising from the get go because of the very fact that we are an island. 
Product market fit is something that is a challenge to a lot of businesses; to ensure that 
they are investing and building a product or service that is actually required or wanted 
by the market and that the market is willing to pay for, and in a format that the market is 
willing to pay for. That is particularly true in the life science sector as you’re seeing 
large multinationals less willing to invest in early stages and more likely to wait until 
their less risky and pay more for them. This means that there is an awful lot of impact 
on the type of capital and the length of time that investors have to carry investments 
before they can actually gain significant traction in a particular market.” 
 
Q: Do you typically find that you have to make modifications to the product 
offerings from the start-up companies?  
“Most do, of the companies that went through our accelerated growth program, 
approximately 60 – 70%, have pivoted which is a fancy way of saying they have 
tweaked or trailed or changed slightly their proposition. Initially they may have thought 
they would get traction in market A but they have found that if you go after A, B and C it 
is a more powerful proposition for the company. That is just the nature of business and 
it think the quicker we can provide a market feedback system to people the better; so in 
that regard we do a lot of work such as act for silicon valley in the US and in the UK, 
we do the same throughout all of our key geographies for our start-ups and we ensure 
that they are familiar with the local market, processes and any issues. The businesses 
can be faced with significant technical, regulatory, financial and market specific 
challenges so we work to ensure they understand these challenges.” 
“We start at the same point as VC’s and that is where our interests diverge, VC’s are 




that the companies we invest in have sufficient capital. VC’s want an exit, so they are 
either going to be bought up by an existing firm to bring in additional capital or private 
equity. We need to ensure that if the early VC fund is looking to exit that there is 
somebody there that can take the place of these funds in that business such that the 
business does not have to be flipped or sold – the goal is to maximise the potential of 
the business.”  
 
Q: What are the biggest challenges you see in the life science sector in the 
medium to long term?  
“The first will be ensuring that there are sufficient types of capital available, which there 
are right now, but really bringing business to scale is the next frontier for us. We see 
very exciting business that really have true global potential selling before they really 
need to sell, possible due to risk aversion or more specific issues.” 
“We also need to have an open and proactive health system so that our companies can 
test, trial and develop their products and services before they internationalise; as the 
first question asked when they go into new areas is “how did you get on in your own 
system?” So we are working closely with the HSC and the department of health in that 
regard because it is hard enough the raise capital without having to navigate complex 
regulatory structures in addition to ensuring that you are building your team and your 
business. That is a challenge that we need to ensure is addressed.” 
“My focus is scale; also there are market opportunities that are going to open up in 
Asia. These are markets that are different to do business in but really with the 
explosion in the number of middle income consumer spending we expect to see very 
significant opportunity and that is why we are increasingly opening offices in China, the 
middle east and the Asian economies.”  
 
Q: Are your goals to grow the number of HPSU’s or stick to a finite number and 
increase the quality?  
“Five years ago we were doing 65 businesses a year now we are doing over 100 
HPSU’s and 100 competitive start funds so we have gone from 65 to 200 in the space 
of five years. Our three year target is to do 550 start-ups, 300 of which are high 
potential and 250 of which are competitive start funds so certainly for this year and next 




because we are doing twice what some of our competitor economies are doing - this 
represents a resource challenge as our business development officers are being asked 
to do a lot more with less people.” 
“In the life science space we have a portfolio of approximately 350 businesses and our 
economic data on them has shown that our job creation and exports from these 
companies have been growing year on year. We have more value added business, in 
that they have moved up the value chain from being commodity suppliers to own brand 
developers to product development companies, to therapeutic businesses, to 
diagnostic businesses to point of care business. We have really seen an explosion in 
terms of the life science start up community because when there was a wider down 
turn a lot of investors started looking closely for the returns that were available and the 
quality of the businesses that were being set up in Ireland. So certainly our indigenous 
life science company base is highly innovative, highly dynamic, highly globalised and 
actually a great place to work. We have some fantastic businesses operating in the 
country that are global leaders.” 
 
Q: Do you see much interaction between the companies?  
“On a sectoral basis we would hold client forums such as CEO forums, CFO, COO and 
founders typically know each other and we bring together leaders of businesses within 
the same area and cross sectorial too.” 
 
Q: Do you have anything else you would like to add? 
“Life Science businesses have to be global from the get go, global systems and the 
macroeconomic environment drivers also impact indigenous businesses.  While most 
talk about consolidation of the larger MNE’s, the flip side to that is that there is an 
insatiable desire amongst the global multinational community for next generation 
technology and opportunity. That really creates an opportunity for economies who are 
investing in the early stage high potential businesses which provide the next generation 
technology which then become international beacons for innovation. It actually creates 
great opportunity, so I think that there has never been a better time to set up an early 
stage life science business because you have more interest from the global market 
now than you’ve ever had before. No one country, no one company, no one economy 
can have a monopoly on the life science space because it is so complex, is multi-




disciplines than ever before. That puts economies like Ireland and those that invest in 
and continue to invest in the research that underpins these businesses and following it 
with early stage seed and venturing funds, incubation and businesses development 
has put us in a very strong position as those global MNE and the general global 
community are increasingly looking for new products and services to meet medical and 
clinical needs of society. As it was put to me once upon a time, if you are fat or fit you 
are going to need some type of medical intervention. So it is a case of what economies 









Appendix 2: Example of interview from a start-up company. 
 
William Gallagher – Co-Founder and CSO of Oncomark Ltd: 
Q: Can you please give an overview of your company and how you developed to 
where you are today? 
“The limited company is Oncomark Ltd, is a spin out company which I established with 
co-founder Steve Penny back in 2007 and really only got going 2 years after that. Our 
strategy at the time was to put in some of our own seed money and we got some EI 
core support. It was a small amount of money to check out the market opportunity of 
the company. The company is focused in the area of medical diagnostics with a 
particular focus in the oncology sector and we were looking at a couple of different 
technologies from my academic lab as initial product opportunities. One of them did not 
pan out, it was originally a product from an EI proof of concept grant which didn’t really 
pan out as we couldn’t validate out diagnostic. The second technology we successfully 
got a US and EU patient issued, it is an image analysis technology and we licenced 
that into Oncomark Ltd as a first product opportunity. In contrast to a lot of other 
companies, from an academic point of give I have a good track record in availing of a 
lot of EU funds. Because the EU was quite supportive of small companies we decided 
to target EU funds directly initially instead of VC funding to really grow the company. So 
the first eighteen months after incorporation we targeted a number of grants from the 
EU which kicked off in the middle of 2009. Since then we have gotten 8 grants from the 
EU totalling close to €5 million which directly fund R&D activities within the company.” 
“We are an R&D heavy company – which is a high risk areas and a lot of the 
discoveries we find we cannot subsequently validate so there is a lot of failure within 
the system, so we are involved in a quite risky area for people to invest in. We were 
fortunate to have that source of funding to do that activity. Our leading product we are 
trying to develop at the moment is an assay for early stage breast cancer where we are 
trying to product if women should get chemotherapy for not.  We have recently licenced 
a technology from TCD where we have a potentially alterative solution technology that 
needs to be validated. But it seems to outperform the market leaders in the space so 
we are probably going to focus a lot of attention within the company on this particular 
product. We are in the process of hiring in a new CEO into the company who has a lot 





Q: Did you approach EI of did EI find you?  
“We approached EI.” 
 
Q: How did you find that process?  
“For the initial EI core grant we participated in a campus company development 
program for about a year previous to the grant. It was a nine month program where 
they take 10 – 12 new venture ideas and go through the process of trying to mature out 
the concept and so Steve and I participated in that. Steve was a mature student and 
had come from an investment funding background for about 15 years in London and 
Japan so he had lot of experience and business acumen. I obviously had a scientific 
background and so he went back and studied biotechnology in DCU and then he spent 
some time in my lab. Together we decided to push forward with the campus company 
development program to really pursue an idea of trying to form a company in the 
oncology diagnostics space. As part of that process we became aware of the supports 
available at EI and we then applied for the core grant.”  
 
Q: Was it mainly the grant you availed of in the early stages, or was there any 
guidance proved such as assistance in developing a business plan?  
“Not really at that stage, the initial support was for scoping out a market area for the 
technology and we subsequently have not gotten any EI support since then. We were 
teeing up some investment about two years ago, we were pushing forward an 
investment round and we had secured in principal EI funding of €250k but were not 
able to match that at that time from external investors. So you could say that we had 
good support in principal from EI but we haven’t subsequently gotten support or any 
direct funding as a company from EI to this point.”  
 
Q: When you went to the EU for funding, did you use your own contacts or did 
you use an EI contacts?  
“We pretty much used our own contacts; I would have a lot of experience in that area 
so I would have been involved in securing funding from the EU for the last 20 years so I 





Q: Have you used any other supports to date, such as NovaUCD or any other 
body?  
“Nova provided indirect support. As a campus company you didn’t get direct support 
from Nova per say – for example there is no support in terms of IPe that’s reserved for 
the academia. But you get indirect support in the sense that they may organise some 
seminar events and obviously we are hosted in NovaUCD where we do have labs and 
office space there but we pay for those as if you would in any other commercial entity. 
There is general support which you pay for.” 
 
Q: In terms of the next stages of the business, how do you see yourself growing 
the company?  
“I think we have been good at getting EU funding but that is insufficient for us. We need 
to go to the next step and get external investment from non-grant funded sources. That 
is the reason we have targeted this new CEO who has successfully commercialised 
two companies previously to the point of sale and so we needed someone who had 
that experience within the diagnostic industry. We have some experience but wouldn’t 
have a lot of industry experience. We needed someone with that experience who could 
drive the business forward and secure external investment. We will also pursue a grant 
funded strategy as well because that lessons the risk for external investors if there is 
some research activity that can be supported by grant funding sources then it reduces 
the amount of money required for the company and lessons their risk.”  
“One of the big targets for us is the SME instrument under Horizon 2020 which is a 
program that funds single SME’s up to €5 million 100% funding plus overhead so it is a 
very good funding model and in particular program which are directly linked to what we 
do.”  
 
Q: In terms of finding your CEO, did you locate him yourself or did you leverage 
contact / advice from a support body such as EI?  
“He was looking at particular technologies coming from Irish institutions and NOVA 
UCD linked me with him and we struck up a friendly conversation. It was a timely 
moment for the two of us as he had just finished with an executive position in his most 





Q: What is the structure of the company at the moment?  
“We have fluctuated between 10 -15 sometimes 20 people within the company which 
would be directly funded and most are research active, some are project management 
and support and there is a layer of executive support around that.”  
 
Q: What are the future plans of the company?  
“We would hope to grow the foot print and employment within Ireland. We have 
projected out if we get some of the external investment and this SME instrument we will 
grow quite rapidly and we will probably not grow beyond a critical size which would be 
maximum around 30-40 people if we are successful.”  
 
Q: At the moment you have no direct EI involvement with the company? 
“No direct involvement at the moment. We would be at the fringes, in principal we fulfil 
the objectives of EI in terms of numbers of people and being a high performing start-up 
but we were kind of a different breed then what they are looking at. They had a six year 
timeframe for participating in the HP company programme but the nature of life science 
takes a lot longer so we have slightly fallen out of that space. Every now and again we 
have been in contact with our point of contact within EI but no real concrete support at 
the moment.”  
 
Q: Is that a decision made by EI or is it a decision that you made as a company – 
i.e. you know that the current EI offerings are not a good fit at the moment?   
“There is no real need for us to go to EI at the moment. Certainly if we go back and 
pursue another round of investment we would consider EI but they have a limited 
amount of money they can provide anyway so we may or may not decide if we are 
going to bring them on board.”  
 
Q: looking back on the development of the company, would you do anything 
differently if you were to start again?  
“There are a few things I would do differently with the benefit of hindsight; certainly 




two years who was quite good for moving from a broadly academic setting into a more 
commercial environment but didn’t have the full experience in the diagnostics industry. 
They had previously been involved in spin-outs and were good at converting 
companies into a formal structure in that sense but didn’t have the wherewithal within 
the investment arena and diagnostics area. If I was to start again I would really hold 
back to find that person to really drive the business forward.” 
 
Q: What were the strengths / weaknesses with regard to your dealing with EI in 
the early stages of your company development?  
“As a weakness, they didn’t really suit our type of company, they probably used to 
dealing with IT companies who are quick turnaround with low potential overheads. 
Whereas life science companies are more of a slow burner and can take a while to 
mature.”  
 
Q: Did you have any difficulties explaining the business concept to EI?  
“Yes, a business concept within biotech can be somewhat nebulous because you can 
be talking about something that is quite abstract so it is not a piece of software. It was a 
potential promise of a new diagnostic but there is a long way to the validation of that 
technology. The drug development space can be 15 years from the proof of concept to 
actually delivering a product. So diagnostics can have a similar timeframe due to the 
validation of the product so it’s hard for people to grasp that.”  
 
Q: Would you have any additional comments on the overall process of starting a 
life science company out of University in Ireland? Areas for development etc.?  
“One of the issues for spinning out is the funding for developing a portfolio of patents is 
not there - what then typically tends to happen is that you come up with a particular 
type of technology you submit a patent and then you have a year of chasing around 
people to try and get the limelight on the technology because there isn’t funds available 
to move it to the more expensive stage of development. Therefore most of the 
academic institutions try to offload the technology or terminate the IP before its gets too 
expensive that then does not allow you to build up a portfolio of IP which is what you 
need for a robust company – i.e. not just having one patent, but having a suite of 




successful spinout from Limerick and was one of the early success within the biotech 
sector in Ireland. They were able to build up a favourable portfolio of IP which is really 
where the value of a life science company is. That is a weakness, probably because of 
the funding models, most of the technology transfer institutions within Ireland don’t 
have the financial wherewithal of the foresight to really build up a portfolio.” 
 
Q: During your development did you approach any established diagnostic or 
biotech companies with a view to forming partnerships? 
“We had some initial interactions but didn’t really do it in great depth because I 
suppose we were trying to formulate and fix our own ideas before we really went out 
there.”  
 
Q: Do you have any additional comments on EI? 
“On an indirect level, from an academic level, we have received a lot of support from 
EI. The two technologies that we did licence into the company were from EI funded 
sources so they were two tech development grants which allowed us to successfully 
bring the technology forward to a point of issuing patents and licencing the technology 
in the first and in the second we are still pending the patent. But from a company 
support point of view, EI have not provided a huge amount. On the academic side 
when I was bidding for the EU grants we always sought very good support from EI for 
coordination support grants. These are small pots of money which help you bid for 
large EU grants which we were never turned down and we were quite successful, 
above 50% for these programs.”  
“So from an academic point of view we got excellent support from EI. Once you step 
over into the company side we found that the supports, at least from our perspective, 
are quite a lot less or at least we haven’t availed of them or actively pushed on them.”  
 
 
 
